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I Clinical and Epidemiologic Characteristics of Psoriasis 
General description 
The term psoriasis is originally derived from the Greek word'psora',meaning'itch'' It is a common 
and chronic skin disease characterised by cutaneous inflammation, abnormal keratmization 
and epidermal hyperprohferation The diagnosis of the disease can usually be established by 
clinical examination When considering the diagnosis psoriasis, careful examination of scalp, 
umbilicus, mtergluteal cleft and nails should be performed Positive findings in these regions, 
be it only subtle, can be indicators of the diagnosis2 There are no laboratory tests available A 
histological confirmation of the diagnosis is not always necessary Classical signs of psoriasis 
are the'signe de la tache de bougie', which refers to the candle wax-like appearance of a plaque 
when its scales are being scratched, and the 'Auspitz sign', which refers to pinpoint bleedings 
that become visible after removing the silvery scales2 3 Although not life-threatening, the 
disease can be disabling physically, socially as well as psychologically Appropiate education 
and advice about the disease and its possible effects is therefore important4^ 
1.1.1 Epidemiology 
Prevalence 
The estimated worldwide prevalence of psoriasis is 1 5-3% among the Caucasian population710 
Nearly 15 million people are suffering from this condition, although its frequency varies widely 
among different ethnic groups Prevalences range from 0% among the Samoan population to 
12% in Arctic Kasach'ye2 Males and females are equally affected The age of onset varies, with 
two peak incidences The early onset psoriasis develops between the ages of 16 and 22, the 
late onset type between 57 and 60 years' ' , 3 The skin lesions are often the first manifestation of 
the disease, however in some cases extracutaneous manifestations come first" This frequently 
hampers the diagnosis, sometimes even for years 
The clinical severity of psoriasis varies widely among patients and is partially dependent 
on the type of psoriasis15 '6 Variable expression of skin symptoms is seen in different disease 
stages Although the condition can sometimes be very recalcitrant and resistant to therapeutic 
interventions, in most cases psoriasis can be treated relatively easy in an outpatient setting 
Exacerbating factors 
The variability m the prevalence of psoriasis among different populations indicates 
susceptibility to psoriasis must be genetically determined17'9 Disease onset and severity, 
however, are influenced by environmental factors as well, as has been shown in several twin 
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studies20"23. It is known that a psoriatic lesion can be elicited by local trauma of the skin (Koebner 
phenomenon)24. Several types of medications, such anti-malarial agents, lithiumcarbonate and 
antibiotics, may aggravate psoriasis or be a causative factor25. Infections, both bacterial as well 
as viral, are well-known for causing exacerbations25·26. Furthermore, a relationship between 
psoriasis has been suggested with 'lifestyle', e.g. obesity, smoking, alcohol consumption4·7'27. 
Many patients report psychological stress to be an important factor28·29. 
1.1.2 Clinical aspects 
Psoriasis is an inflammatory disease which is characterized by a pattern of spontaneous 
remissions and exacerbations. Predelection sites of the skin symptoms are the extensor 
surfaces of elbows and knees, and the scalp. Although the most common form is characterized 
by the presence of symmetrical, sharply demarcated, erythematous plaques with a silvery 
scaling, psoriasis has a variety of clinical presentations2·ια30. 
Types of psoriasis 
Plaque psoriasis/psoriasis vulgaris, as mentioned above, this is the most common form, occurring 
in about 90% of all cases. Patients suffer from coin-size to palm-size erythematosquamous 
plaques, sometimes coalescing to even larger areas (figure 1). Itch may be present, especially 
when new lesions are developing. 
Guttäte psoriasis is a form of psoriasis which is frequently the result of a streptococcal 
infection31·32. Instead of the characteristic plaques, droplet-like lesions are seen, primarily 
involving the trunk. Their appearance is abrupt, typically occurring as an acute eruption in 
children or young adults without a previous history of psoriasis. 
Figure 1: plaque psoriasis 
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Pustular psoriasis is a severe and often therapy-resistent form of psoriasis which is 
characterized by the presence of erythema, scaling and sterile pustules with erosions. The 
most severe form, the von Zumbusch type, is associated with high fevers, malaise, diarrhea and 
leukocytosis and is potentially life-threatening33. Hepatic abnormalities are frequently seen. 
Inverse psoriasis refers to a type of psoriasis involving the intertriginous areas, such as the 
axillary, inguinal, perineal, genital, intergluteal and inframammary regions. 
Erythrodermic psoriasis is an extensive form of psoriasis, affecting the total skin. As the 
generalized erythema and scaling can give rise to very severe symptoms such as dehydration, 
hypo-or hyperthermia, protein loss and imbalance ofelectrolyte metabolism, patients suffering 
from erythrodermic psoriasis should be admitted to the hospital34. This form of psoriasis is 
regularly seen after abrupt withdrawal of corticosteroids and after the use of medications 
known to influence psoriasis. 
Besides skin symptoms, some patients with psoriasis also experience extracutaneous 
manifestations of the disease: involvement of nails and joints. Nail symptoms such as pitting, 
distal onycholysis or subungual hyperkeratosis are seen in 10-50% of all patients35 (figure 2). 
The joints are affected in about 10-20% of patients36. Psoriatic arthritis does not necessarily 
have to be accompanied by skin symptoms, as it can be present up to years prior to the first 
cutaneous manifestation. 




The psoriatic lesion consists of three basic morphologic elements: erythema, induration and 
desquamation. These are the resultant of histological alterations of the psoriatic skin. The 
histological picture of psoriasis varies, dependent on the stage and activity of the lesion. The 
main changes consist of focal parakeratosis, epidermal acanthosis, elongated rete ridges and 
the presence of inflammatory infiltrates in both epidermis as well as dermis2 as shown in figure 
3. Lymphocytes are the predominant cells in these infiltrates, although polymorphonuclear 
leukocytes (PMN) are present as well. In fact, PMN are the cells which form the psoriasis-
specific spongiotic pustules of Kogoj and Munro micro-abcesses, in stratum spinosum and 
stratum corneum respectively37. Finding either one of these PMN accumulations in histological 
examinations is highly diagnostic for psoriasis. 
II Immunopathogenesls of psoriasis 
The pathogenesis of psoriasis is complex. Various celltypes have been identified to play a role 
in the disease process. Most of them can occur both in the psoriatic lesions as well as in the 
systemic compartment. The lesionai cells have been extensively studied3843, since psoriasis 
was initially thought to be the result of a skin problem. Nowadays it is widely accepted that 
psoriasis is a systemic disease instead. In the past decades, evidence supporting this hypothesis 
has been accumulating4451. 
A short outline of the changes in lesionai skin and in the peripheral blood compartment 
will now be given. 
Figure 3: Histologic features of psoriasis: parakeratosis, epidermal acanthosis, elongated rete ridges 
and the presence of inflammatory infiltrates in both epidermis as well as dermis 
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1.2.1 Outline of the immunopathogenesis of psoriasis 
Psoriasis is fundamentally an inflammatory skin condition with reactive abnormal epidermal 
differentiation and hyperproliferation. Current research suggests that the inflammatory 
mechanisms are immune based and most likely initiated and maintained primarily by T-cells 
in the dermis. 
Recently, several reviewers have presented the current understanding of the 
immunopathogenesis of psoriasis48·49·52. The concept of this immunopathogenesis has shifted 
from a simple focused defect to a disorder in immunity, and in particular of innate immunity. 
One of the important events involves activation of Langerhans' cells. To facilitate antigen-
presentation to a T-cell, the Langerhans cell must migrate from the skin to regional lymph 
nodes. Presentation of an as yet unidentified antigen to the T-cells, as well as a number of co-
stimulatory signals, triggers an immune response, leading to T-cell activation and the release 
of cytokines. The co-stimulatory signals are initiated via the interaction of adhesion molecules 
on the antigen-presenting cells, such as lymphocyte function-associated antigen (LFA)-3 and 
intercellular adhesion molecule-1, with their respective receptors CD2 and LFA-1 on T-cells. 
The T-cells travel back to the skin where they will be re-activated, which, in combination with 
the local effects of pro-inflammatory cytokines leads to the epidermal hyperproliferation, 
inflammation and cell-mediated immune responses observed in psoriasis. 
Interference with the migration of Langerhans cells could be a potential target for 
anti-psoriatic therapies. The tumor necrosis factor (TNF) type 2 receptor was identified as an 
important factor in this cell migration53·54. TNF, as a primary cytokine, signals either anti- or 
proinflammatory secondary cytokines. Its eventual effect is dependent on the equilibrium 
between TNF and other cytokines, and determines whether an inflammatory response will be 
a strong ora weak one. It was learned that inhibition of these cytokines reduces and weakens 
inflammatory processes55·56. To a lesser extent, the abovementioned abnormalities can be 
observed in symptomless skin of psoriatics. 
In peripheral blood, important changes have been reported. These are summarized in 
the overview in table I. 




Pro-inflammatory cytokines { {IL-10, IL-18TNF-a, IFN-y) 
Activated T-cells Î 




Table I: peripheral blood parameters in psoriasis 
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As for their relevance m this thesis, the changes in peripheral blood with respect to T-
cells, T-cells expressing NK-receptors and cytokines will be described in more detail. 
1.2.1.1 T-cells 
Although data on T-cells are not umvocal, there is accumulating evidence pointing toward 
this cell type as one of the key players m the pathogenesis of psoriasis, both systemic as well 
as cutaneously. It has been suggested that circulating T-cells are activated and subsequently 
recruited from the circulation during the development of psoriatic plaques. 
In psoriasis, there is an apparent deviation of T-cell differentiation towards type-
1 T-helper and T-cytotoxic cells. This is reflected by the increased percentages of T-cells 
expressing activation markers m peripheral blood. Elevated levels of CD45RO+, CD4+CD45RO, 
CD4+CD25+, CD8+CD25+, CD4+CD54+, CD4+HLA-DR+ and CD8+HLA-DR+, as compared to 
healthy controls, have been reported57"60. The number of peripheral blood CLA- (cutaneous 
lymphocyte-associated antigen-) expressing T-cells in psoriatic patients was found to be 
increased as well61. CLA is expressed on skm-hommg cells, indicating that m psoriasis more 
cells are intended to migrate to the skin, in comparison to healthy subjects 
Additionally, a loss of function of CD4-i-CD25(high)CTLA4+Foxp3(high) cells, the so-
called regulatory T-cells has been found in psoriasis patients62. Decreased suppressor activity of 
regulatory T-cells possibly results in hyperproliferation of pathogenic T-cells63. This cell type has 
recently gained interest among investigators because of its suggested mechanism of action in 
other diseases. Similarities between those diseases and psoriasis have made them aware of the 
possible role of the regulatory T-cell in the latter 
1.2.1.2 T-cells expressing NK-receptors 
This is a subset of T-cells which express a NK receptor, in addition to theT-cell receptor (TCR) As 
for the NK cells, NK-T-cells have distinct functions, which are dictated in part by organ-specific 
mechanisms64 The presence of NK-T-cells in psoriatic plaques was first described by Nickoloff65. 
In peripheral blood of psoriasis patients, the number of cells expressing NK-cell markers 
CD16, CD56, CD94 or CD158a are reduced as compared to healthy controls66 67. This finding 
corresponds with the results of similar studies in auto-immune disease, possibly suggesting a 




T-lymphocyte cytokine profiles can be categorized as TI and T2. Psoriasis is assumed to be 
a Thl mediated disease68. Increased amounts of several type I cytokines have been found in 
peripheral blood of psoriasis patients. Expression of IL-1, IL-6, IL-8, IL-10, IL-12,TNF-aand IFN-γ 
was found to be augmented6973.This overproduction of pro-inflammatory cytokines, induced 
by activated T-cells, is thought to stimulate the proliferation of keratinocytes and, via this 
pathway, seems to be of importance in the development of psoriatic plaques. 
To date, it remains to be answered whether the changes in the peripheral blood of 
psoriatic patients are the primary event or secondary. 
1.2.2 Focus of research interest 
The Τ lymphocytes in the psoriatic plaque consist mainly of CD4+ and CD8+ cells7476. Their 
distribution is clear: the CD4+ cells occur predominantly in the dermis, whereas the CD8+ T-
cells are found mostly in the epidermis. Most of theT-lymphocytes in lesionai skin are activated, 
expressing CD25 and/or HLA-DR77. Baker et al78 found that even in distant uninvolved skin of 
psoriatic patients, significant numbers of T-cells can be found. Healthy skin only sporadically 
contains T-cells. Other T-lymphocytes which have been reported to be present in lesionai 
psoriatic skin are CD45RO-I-, CLA-i-, CD94+ and CD161 +T-cells7981. None of these celltypes on 
itself is specific for psoriasis, as they can be found in other skin diseases as well43,82·83. 
With respect to the circulating T-cells subsets in psoriasis, no clear pattern of changes 
was observed so far. In this thesis, we consistently investigated a specific panel of T-cell 
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Cytotoxic T-cells 
Memory-effector T-cells, monocytes, macrophages, B-cells 
Naive T-cells, B-cells, monocytes 








1.3.1 General therapeutic guidelines 
Numerous therapies are available for the treatment of psoriasis, both topical as well as 
systemic therapies. In choosing an appropriate therapy for a patient, disease severity, patients 
preference and the expected response should be taken into account. 
1.3.2 Current Treatments for Psoriasis 
1.3.2.1 Topical Medications 
Emollients are used as an adjunct to other topical or systemic anti-psoriatic therapies. They 
moisturize and soften the skin and reduce symptoms of itch and tenderness. 
Keratolytics are applied on hyperkeratotic plaques in order to remove the scaling characteristic 
in psoriasis. By doing this, the penetration of other topical anti-psoriatic therapies is enhanced, 
leading to better clinical results84. 
Dithranol has been used to treat psoriasis for more than a century. It is the synthetic 
analogue of chrysarobin, which is derived from the bark of the Araroba tree, and was found to 
be effective in the treatment of psoriasis in 1876. Dithranol can be prescribed as an ointment, 
cream or paste. Although it is a very effective and safe therapy, application of this therapy in 
an outpatient setting used to be difficult due to the presence of side effects such as dithranol 
staining of skin and clothes85. With the introduction of the short contact principle of dithranol 
in 1980, it became possible to apply dithranol treatment in day care centers or at home86. 
Dithranol is unstable and undergoes spontaneous oxidation, especially when formulated in 
low concentrations. The intermediate oxidation products are thought to be responsible for 
both the antipsoriatic effect and the irritation caused by dithranol67. Side effects are usually 
minimal, although post-treatment erythema can be problematic. 
Topical corticosteroids are the most popular topical treatment of psoriasis. Corticosteroid 
preparations are effective, due to their combined anti-inflammatory, immunosuppressive and 
anti-mitotic properties, and convenient to use. Dermatosteroids are capable of inducing a 
rapid clinical respons, dependent on potency of the preparation and application schedule. 
Local as well and systemic side effects of topical corticosteroids consist of atrophy, 
teleangiectasia, striae, hypopigmentation, tachyphylaxis and suppression of the pituitary-
adrenal axis (when applied on large body areas)88. Abrupt cessation of therapy may result in a 
relapse, sometimes with a different morphology, such as pustular psoriasis89. 
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Vitamin D3 derivatives have become an established anti psoriatic therapy during the past 20 
years They act on vitamin D receptors m the epidermis, resulting in inhibition of cell division 
and a promoting effect on cell differentiation90 Comparative studies have shown their effect 
is similar to that of potent topical corticosteroids Skin irritation is the mam adverse event, 
occurmg in approximately 25% of patients using calcipotnol91 Vitamin D3 analogues are a 
relatively safe therapy, provided that patients do not use more than the recommended licensed 
daily or weekly dose If this dose is exceeded, continuation of therapy has to take place under 
close supervision of blood parameters, as hypervitammosis D3 may lead to hypercalcaemia92 
Coal tar has been used for the treatment of psoriasis for over a century and is probably the 
oldest topical therapy for the disease93 Although very effective, it has its disadvantages such 
as its odour and discoloration of clothes Therefore, tar is predominantly used in day care 
centers and in-patient settings Adverse effects of tar treatment are folliculitis, phototoxicity 
and irritative dermatitis The possible carcinogenic effects of tar have, up until now, been the 
subject of many investigations94 97 So far, no consensus with respect to the potential hazardous 
consequences of tar treatment was reached 
Topical calaneunn inhibitors, such as tacrolimus and pimecrohmus have shown to be 
effective only in facial and flexural psoriasis98,00 Both ointments are approved for use in psoriasis 
only recently By blocking the calcmeurm complex, they are able to inhibit T-cell activation, 
thus suppressing the local inflammatory reaction'01 As these therapies do not exhibit the 
disadvantages which are seen with other topical treatments, such as atrophy and tachyphylaxis 
(corticosteroids), irritation (dithranol, vitamin D3 derivatives) and practical limitations (tar, 
dithranol), they were initially considered to be very safe In animal tests however, an increased 
risk of malignancies was claimed in association with tacrolimus and pimecrohmus, leading to 
label warnings for both therapeutics in 2005,02 
1.3.2.2 Photo(chemo)therapy 
Phototherapy isthe therapeutic use of ultraviolet irradiation without exogenous photosensitizer 
Photochemotherapy is the combined use of the drug psoralen and ultraviolet A radiation to 
achieve an effect not achieved with the individual components alone 
Phototherapy is a well established treatment modality in psoriasis It has shown to 
be an effective therapy for psoriasis'03105, although the exact mechanisms of action of both 
ultraviolet Β (UVB) and ultraviolet A (UVA) phototherapy remain to be clarified Probably, direct 
phototoxic effects as well as immunomodulatory effects play a role m the beneficial results 
which can be achieved by using ultraviolet light as a therapeutic'06 Phototherapy is indicated 
in those cases of psoriasis which cannot be treated satisfactorily with topical therapies alone 
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UVB light has wavelengths ranging from 290-320 nanometer. It can be given as a whole 
body-treatment or as a localised therapy. There are two types of UVB. broad- and narrowband 
UVB. Narrowband UVB might be more effective, but has a higher risk for sunburn reactions The 
mechanism of action of UVB is still unknown. It is hypothesised that UVB leads to a reduction 
of DNA-synthesis m epidermal cells and alters the immune respons of the skin 
UVA light is UV light with a wavelength range of 320-400 nm By itself is relatively 
ineffective, unless used with a hght-sensitismg medication, such as psoralen The combination 
of UVA with psoralen is called PUVA after psoralen is ingested or topically applied to the skin, 
the patient is exposed to a light unit with ultraviolet lamps PUVA therapy is highly effective 
and able to induce long remissions. 
The combination of PUVA with a systemic retinoid is called Re-PUVA'07, and is a popular 
therapy throughout Europe Its primary advantage is the reduction of the UVA exposure. 
The most common side effects of PUVA are pruritus and erythema of the skin, and 
nausea108 The mam adverse effect on the long term is the higher risk of developing skin cancer, 
as compared to the non-PUVA treated population109110 This risk is proportional to the extent of 
exposure to PUVA. Furthermore, photo damage following extensive PUVA treatment leads to 
premature skin aging11'. 
1.3.2.3 Systemic Medications 
These are usually indicated when topical treatments and photochemotherapy have proven 
to be ineffective As these therapies have stronger effects than topical treatments, they are 
preferentially suited for severe and extensive forms of psoriasis All mentioned therapies have 
adverse effects, due to their systemic mechanism of action. The seriousness and extensiveness 
of these unwanted symptoms various between individuals. The prescription of systemic 
therapies for psoriasis is preferably carried out by a dermatologist, taking into consideration 
the evidence based guideline112. 
Methotrexate 
Methotrexate is an analog of folic acid. It causes a reduction of reduced folates by competitive 
inhibition of the enzyme dihydrofolate reductase (DHFR) This leads to a decrease in mitotic 
activity and inhibition of DNA synthesis 
Folic acid antagonists have been the first choice systemic treatment of severe psoriasis. 
The first description of their positive effect in psoriasis was published in 1951 by Gubner113. 
Methotrexate was registered in 1971 for use in severe psoriasis. It is administered either orally or 
subcutaneously. The recommended dose for use m psoriasis varies from 10-22,5 mg per week. 
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Maximal improvement of psoriasis while using methotrexate is reached after approximately 
8-12 weeks. Efficacy reports have described an improvement of severity of more than 75% in 
up to 90% of patients1"' 
Common side effects of methotrexate are gastro-mtestmal complaints, fatigue, 
headache and malaise Careful monitoring of blood cell counts, haemoglobin, haematocnte 
and liver chemistry should be performed1,5. In order to prevent adverse effects of methotrexate, 
folic acid is added to the therapy Of concern is the liver toxicity of methotrexate. Liver 
fibrosis and cirrhosis may develop after long-term use in up top 27 % of the patients11611β 
It is recommended to obtain a liver biopsy after a cumulative dose of 1,5 grams, although 
the need for liver biopsies to monitor liver damage is still controversial119121. Methotrexate is 
teratogenous. Adequate contraception is required for both male and female patients, during 
treatment and up to three months after discontinuation as well122123. 
Contra-mdications for the use of methotrexate are impairment of renal or hepatic 
function, severe anaemia, thrombocytopenia, bone marrow hypoplasia, leukopenia, hepatitis, 
liver cirrhosis, pregnancy and excessive alcohol intake123 
Aatretin 
Acitretm is a synthetic retinoid. It has antiproliferative and anti-inflammatory effects and 
normalizes epidermal cell proliferation, differentiation and keratmisation12". Indications for 
therapy with acitretm are severe and extensive therapy-resistant forms of psoriasis, such as 
psoriasis pustulosa or erythrodermic forms of psoriasis The recommended initial dose of 
acitretm is 25-30 mg daily for 2-4 weeks. Thereafter, a maintenance dose can be given. The 
toxic dose of acitretm is close to its therapeutic dose Common side effects are mucocutaneous 
problems, such as dryness of the eyes and the nasal and oral mucosa, cheilitis, xerosis of the skin, 
palmoplantar desquamation and pruntis125. Other adverse effects are hair loss and brittle nails, 
and increases m serum cholesterol and triglyceride concentrations These adverse events are 
usually reversible, and disappear after adjustment of the dosing schedule or discontinuation 
of therapy. Long-term treatment with acitretm may result in osteoporosis, degenerative 
spondylitis and skeletal hyperostosis The teratogenicity of acitretm is a major inconvenience. 
Adequate contraception should be used for at least two years after discontinuation of therapy, 
as acitretm (after re estenfication) accumulates in fatty tissues for up to two years 
Cyclosporin 
Cyclosporin is a immunomodulatmg therapy. It binds to cyclophilm in the cytoplasm This 
cyclosporm-cyclophilm complex inhibits the enzyme calcineurm, which plays a pivotal role in 
the trancription of many cytokines. A (reversible) reduced T-cell proliferation is the resultant 
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Cyclosporin also affects antigen presenting cells and keratinocytes. It is an appropiate therapy 
for severe cases of psoriasis, although its side effects are numerous126128. Dose-dependent 
nephrotoxicity may result in irreversible renal damage. Hypertrichosis, gingival hyperplasia, 
hypertension and tremor occur relatively frequent. Careful monitoring of patients during 
therapy is required. Liver and kidney function, haematological parameters and blood pressure 
should be assessed at regular intervals. The maximum daily dose of cyclosporin in psoriasis is 
5 mg. Because of its strong immunosuppressive potential there are many contraindications: 
impaired kidney function, immunosuppressive, cytotoxic or nephrotoxic co-medication, 
uncontrolled hypertension,active infections, malignancies, pregnancy and immunodeficiencies 
are important examples129. 
1.3.3 New and Adjusted Treatment Modalities 
Recently, important innovations have been reached in the treatment of moderate-to-severe 
psoriasis: 
(1) the adjustment of an existing classical pharmaceutical. In this respect the improvement of 
fumarates is a challenging development. 
1.3.3.1 Fumarie acid esters 
Fumarie acid, an intermediate in the citric acid cycle, was first shown to be effective in psoriasis 
in 1959 by the German chemist Schweckendiek, who suffered from psoriasis himself. He 
hypothesized that disturbances in the citric acid cycle played a role in the pathogenesis of 
psoriatic plaques. Schweckendiek experimented with several forms of fumarates, and finally 
developed a mixture of fumarie acid esters (FAEs)130. These ester derivatives of fumarie acid 
have a higher efficacy and bioavailability than fumarie acid itself. Until 1990, data about 
the effectiveness of FAEs were based on case reports and open studies. Only then, the first 
comparative study with FAEs in psoriasis was published130. This revealed the combination of 
dimethylfumarate and monoethylfumarate to be superior to dimethylfumarate alone. Clinical 
trials performed since 1990 have shown FAEs to be an effective and relatively safe therapy for 
the treatment of severe psoriasis131'132. 
A defined mixture of FAEs, consisting of dimethylfumarate (DMF) and salts of 
monoethylfumarate (MEF) has been licensed in Germany since 1994. Monomethylfumarate 
(MMF), which is formed following hydrolysis of DMF, is regarded as the active metabolite. The 
exact mode of action of FAEs is still not fully understood. Experimental data so far reveal FAEs 
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target mainly T-cells and keratinocytes. A persistent decrease in lymphocyte count during FAE 
therapy was shown in several studies'33·134. Furthermore, a monomethylfumarate-induced 
modulation of cytokine secretion in activated T-cells has been described, indicating a skewing 
from the Thl-mediated T-cell response to a Th2-like pattern'3 5 . With respect to its effect on 
the keratinocyte, evidence for inhibition of keratinocyte proliferation, induction of intracellular 
calcium release and inhibition of expression of ICAM-1 has been reported136. 
FAEs are almost completely absorbed in the small intestine, explaining the high 
frequency (-56%) of gastrointestinal complaints among patients. Other frequent side effects of 
FAE therapy are flushing (sudden redness of the skin combined with a strong heat sensation), 
headache, nausea and tiredness. Eosinophilia, lymphocytopenia and leukocytopenia are 
observed as well. Most adverse events occur during the first three months of treatment. 
Although non-serious side effects, both gastrointestinal complaints as well as flushing can be 
very disturbing. Drug withdrawal rates of 7% have been reported'32. 
The high incidence of adverse events and the resulting high percentage of early 
discontinuation of FAE therapy has challenged researchers to develop a new fumarate therapy 
with equal efficacy and less disadvantages than the current formulation. 
FAG-201 
This is the provisional name of the second-generation fumarate therapy, which has recently 
been under investigation in an international multi-center study for licensing purposes137. FAG-
201 consists of dimethylfumarate (DMF), as enteric-coated microtablets in capsules. Numerous 
in vitro effects ofdimethylfumarate have been described'38 '41, which have led to the conclusion 
that dimethylfumarate is the main active component of the currently registered FAE mixture. 
An overview of the main effects of DMF is depicted in table III. 
In order to reduce the cumbersome adverse events and to increase patient compliance, 
a monotherapy was developed consisting ofdimethylfumarate in the same concentration as in 
the FAE mixture, but without further additions: FAG-201. In dose finding studies, a daily dose of 
720 mg proved to be the most effective in psoriasis142. 
In vitro effects of dimethylfumarate: 
Î Apoptosis 
Expression adhesion molecules i 
Production pro-inflammatory cytokines I 
• Dendritic cell differentiation I 
NFKB-dependent cellular activation pathways I 
Table III: summary of the in vitro effects of DMF 
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(2) biologicals have revolutionised anti-psoriatic therapy 
The implication of immunologic events to be important in the pathogenesis of psoriasis, has 
led to the search for therapeutics with specific immunologic effects.Therefore, biologic agents 
derived from recombinant DNA-technology have been developed. These proteins all have an 
inhibitory effect on the inflammatory process of psoriasis. Four major mechanisms that explicate 
the immunomodulatory effects of biologicals are identified: (1) inhibition ofT-cell activation, 
(2) reduction of pathogenic T-cells, (3) immune deviation from aThl toaTh2 response and (4) 
blocking the activity of inflammatory cytokines. All of these mechanisms result in reduction of 
inflammation and, consequently, reduction of the clinical signs of psoriasis"13. 
The nomenclature of biologic agents is relatively easy to understand. The suffix of the 
specific therapy denotes its class: receptor-antibody fusion proteins end with -cept, names 
of fully human monclonal antibodies end in -umab, names of humanized monoclonals in 
-zumab and those of chimaeric antibodies end with -ximab. 
Momentarily, there are two major groups of biological therapies for psoriasis: agents 
directed specifically against T-cells or antigen presenting cells and agents targeting tumour 
necrosis factor-α (TNF-a). The clinical effects of biologies are promising, they are well-tolerated 
and have a favourable safety profile when compared to the established anti-psoriatic 
treatments144,4*. However, it must be kept in mind, that for most of these treatments, no long-
term data concerning safety are available for the indication psoriasis. It has been hypothesized 
that long-standing use of biologicals is likely to induce malignancies (mainly lymphomas) due 
to their interference with the immune system147. So far, there is no evidence for an increased 
risk of lymphomas in association with the use of biologicals. However, long term monitoring 
will be needed to assess the safety of immunobiologics after prolonged use. 
1.3.3.2 Agents targeting T-cells 
Alefacept 
Alefacept is the first biologic officially approved for treatment of psoriasis in the USA, Canada 
and Switzerland. It is a fusion protein consisting of the extracellular CD2-binding portion of 
leukocyte function-associated antigen 3 (LFA-3) and the Fc portion of human IgGI. Alefacept 
binds to CD2 on the surface of T-cells, preventing the interaction between CD2 and LFA-3 on 
antigen presenting cells (APC's) and thus preventing lymphocyte activation. Presumably by 
bridging between CD2 on target lymphocytes and immunoglobulin Fc receptors on cytotoxic 
cells (e.g. NK cells), alefacept causes a reduction in CD2+ lymphocyte subsets as well, primarily 
in the CD45RO+ population. Alefacept should be administered weekly, as a course of 12 
successive weeks. It is given in intramuscular injections of 15 mg. A phase III study of the 
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efficacy of a 12 week course of alefacept treatment showed that 57% of the patients reached a 
PASI 50 at any time during the treatment period, and 33% reached a PASI 751',8 
The onset of response to alefacept is slow It may require at least one full 12-week course 
of treatment before the effectiveness of the treatment can be determined 
Alefacept induces a reduction in the number of CD45RO+ memory T-cells149 ,50 
Therefore, weekly monitoring of T-cells is advised during and after treatment with alefacept 
Studies with patients receiving up to 6 courses of alefacept have not shown opportunistic 
infections, an increased risk of malignancy or clinically significant signs of immunosuppression 
lodate'5 1 
Efalizumab (Rapava®) 
Efalizumab is a humanized murine monoclonal antibody against CD11 a, a subumt of leukocyte 
function-associated antigen-1 (LFA-1), which is expressed on the surface of T-cells and other 
leukocytes Binding of efalizumab to CDIIa prevents the interaction between LFA-1 and 
intracellular adhesion molecule 1 (ICAM-1), its partner molecule, which is expressed on other 
cell types, such as endothelial cells and keratmocytes152 This interaction is important for 
activation, adhesion and migration of T-cells to the site of inflammation The blockade induced 
by efalizumab is reversible and does not deplete T-cells 
Efalizumab is self-administered subcutaneously, in once-weekly doses In order to 
prevent a first-dose reaction (headache, nausea, vomiting and fever), an initial conditioning 
dose of 0 7 mg/kg should be given, followed by weekly doses of 1 mg/kg body weight153 The 
onset of the response to this therapy is relatively rapid, with noticeable results as early as 4 
weeks After 24 weeks of treatment with efalizumab, 44% of patients had achieved a PASI 75 
and 67% a PASI SO'54 In 30 percent of cases, a PASI decrease of at least 50% was maintained 12 
weeks after discontinuation of therapy 
Adverse events reported during or after the use of efalizumab are relatively few There 
are no associated opportunistic infections or signs of immunosuppression, nor is there an 
increased risk of end-organ toxicity or malignancy However, many patients experienced flares 
after discontinuation of therapy155 The package insert of efalizumab recommends regular 
monitoring of platelets, since m clinical trials thrombocytopenia was observed in a few cases 
1.3.3.3 TNF-α blocking agents 
Tumour necrosis factor-α is a pleiotropic inflammatory cytokine It serves a variety of functions, 




TNF can bind to its receptors p55 and p75 either directly via cell-cell contact or indirectly 
in its soluble form. These receptors are expressed on all somatic cells156. 
Since TNF-a exerts many functions, it is suggested to be important in a variety of 
diseases. In psoriasis, TNF is prominent in active plaques157, there is an increased level of TNF in 
serum which fluctuates with disease severity158, and TNF-α is important in the initial cytokine 
cascade and in keratinocyte activation inducing Langerhans'cell migration. An overview of the 
key actions of TNF-α in psoriasis is given in table IV. 
A substantial amount of research has been performed concerning TNF-α therapies 
and anti-TNF-a therapies. TNF-α blocking agents have shown to be effective in psoriasis, 
with a favourable safety profile. They are capable of inducing rapid disease improvement 
and long remissions. An important limitation of these therapies is the risk of reactivation of 
latent tuberculosis, which often has a severe and disseminated character159. Before initiation 
of therapy, all patients should undergo tuberculosis screening in order to prevent this. Other 
disadvantages are the risk of opportunistic infections, development of specific antibodies and 
the high costs of TNFa- blocking therapy1 6 0 - 1 6 3. 
Examples of TNF-α blocking agents currently used for the treatment of psoriasis are 
etanercept (Enbrel®) and infliximab (Remicade®). Several other anti-TNF treatments are used 
in other inflammatory diseases or still under investigation1 6 4 1 6 7. The psoriasis-relevant TNF-
blocking therapies will be discussed below. 
Etanercept (Enbrel®) 
Etanercept is a construct of two TNF receptor p75 extracellular domains, bound to the Fc 
region of human IgG. It binds to TNF with greater affinity than natural receptors. Etanercept 
is not specific for TNF-α, as it also binds TNF-ß158. Momentarily, etanercept is licensed as a 
monotherapy for psoriasis. In the future, combination therapy with methotrexate will probably 
be introduced. This combination is used in rheumatology for several years and proved to have 
a favourable efficacy and safety profile169. 
T-lymphocytes f IL-1, IL-6and IL-8 Increasedinflammation 
Endothelium f VEGF Increased cell infiltration 
t adhesion molecules Increased angiogenesis 
Hepatocytes f acute phase response Increased serum CRP 
Epidermis t keratinocyte hyperproliferation Skin plaques 
Table IV: primary effects ofTNF-α on different celltypes in psoriasis. VEGF = vascular endothelial 
growth factor. CRP = C-reactive protein 
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Etanercept is self-administered subcutaneously in twice-weekly doses of 25 mg The 
recommended starting dose is 50 mg twice weekly, for a maximum of 12 weeks. A phase III 
clinical trial showed 34% of patients achieved PASI 75 after 12 weeks of treatment with 25 mg 
etanercept twice weekly, and 49% after 24 weeks of treatment A twice weekly dose of 50 mg 
resulted in 49% and 59% of patients achieving PASI 75 after 12 and 24 weeks respectively170 
The onset of the clinical response to etanercept is relatively rapid, with results becoming visible 
within four weeks of treatment. 
The mam adverse events observed during etanercept therapy are injection-site 
reactions171. Allergic reactions, anaemia and demyelmatmg disorders have occurred in rare 
cases172 In general, therapy with etanercept is well tolerated 
Infliximab 
Infliximab, a chimeric TNF-bmdmg monoclonal antibody binds and neutralizes both 
soluble and trans-membrane bound TNF-a. It is capable of killing TNF-a expressing cells by 
both complement-mediated toxicity and antibody-dependent cell-mediated toxicity173 
Immunohistochemical studies have shown rapid and dramatic decreases in epidermal 
inflammation and normalization of keratmocyte differentiation m psoriatic plaques during 
infliximab therapy174 Reduction of the PASI with at least 75% was reported m up to 81 8% of 
patients175. Infliximab is administered intravenously, usually in doses of 3-5 mg/kg, every 4-8 
weeks Because of the potential risk of infusion reactions, administration of infliximab should 
be performed by health care professionals, and the patient should be carefully observed after 
infusion.The respons to infliximab is rapid, with a median time of 4 weeks After discontinuation 
of active treatment, the response can last for weeks'76 Beside infusion reactions, which occur 
in approximately 10% of patients, treatment with infliximab can lead to the formation of 
antibodies. This is probably due to its chimeric character, which leads to immunogemcity.The 
antibodies are asscociated with a loss of response to therapy and with a higher incidence of 
infusion reactions177. More than the other biologicals, infliximab increases the risk of infection 
Reactivation of latent tuberculosis (TB) has been reported by several authors15917β 1β0. 
Adalimumab (Humira®) 
Adalimumab is a fully human IgG 1 monoclonal antibody specificfor humanTNF-α It is produced 
by recombinant DNA technology in a mammalian cell expression system Adalimumab both 
blocks the interaction ofTNF-a with the p55 and p75 cell surface TNF receptors and modulates 
TNF-mduced or -regulated biological responses. It is administered by health care personnel, 
as a subcutaneous injection of 40 mg every other week. Side effects of this therapy are 
comparable to those of other biologicals, eg. reactivation of latent tuberculosis and risk of 
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infections Injection pain is common as well Efficacy studies have shown 75% PASI reduction 
m 53% of patients when treated with adalimumab 40 mg every other week'81 Side effects of 
adalimumab are comparable to those of other biologicals In rare cases, the use of adalimumab 
has led to the development of antmuclear antibodies (ANA) and demyelmatmg disease'82 '83 
The ANA conversion does not seem to be of clinical importance With respect to demyelmatmg 
diseases, caution should be taken when prescribing adalimumab to patients with preexisting or 
recently developed demyelmatmg disorders'84 In the Netherlands, adalimumab is licensed for 
use in psoriatic arthritis since 2005 Registration for use in psoriasis was obtained m December 
2007 
Onercept 
Onercept is a recombinant form of the human soluble p55 TNF receptor As the primary target 
of other anti-TNF agents is the p75 receptor, the introduction of onercept was considered of 
clinical and theoretical interest Onercept neutralizes the effect ofTNF-a by forming high-affinity 
complexes185 It was first introduced as a potential new biological for the treatment of Crohn's 
disease As pharmacokinetic and pharmacodynamic studies in healthy volunteers revealed 
a favourable safety profile and results of phase II studies in Crohn's disease were promising, 
studies in psoriasis were started as well Based on the role of TNF m the pathogenesis of 
psoriasis and the efficacy of other TNF-α blocking agents in psoriasis, it was thought onercept 
could be a suitable treatment for psoriasis, too186 
Onercept is administered three times per week, m subcutaneous doses of 150 mg 
In phase II studies, 54% of patients demonstrated a 75% or more improvement in PASI after 
12 weeks of therapy and 74% an improvement of at least 50% The first clinical results were 
observed as soon as two weeks after initiation of therapy Side effects were relatively few, 
although injection site reactions occurred more than m placebo treated patients'86 The 
unfavorable risk-benefit profile of onercept led to preliminary termination of the phase III 
studies, based on the recommendation of a Data and Safety Monitoring Board (DSMB) 
Combination treatments 
Except as monotherapies, the above-mentioned treatments can also be used in combination 




IV Methods to score psoriasis disease severity 
1.4.1 The Psoriasis Area and Severity Index 
The assessment of psoriasis disease severity is a complex process, as both subjective and 
objective factors are involved. In clinical trials, the most commonly used outcome measure 
to assess the severity of psoriasis and evaluate the effect of therapy is the Psoriasis Area and 
Severity Index (PASI). The first description of this severity determinant was published by 
Fredriksson and Petterson in 1978,95.The PASI-score is based on the quantitative assessment of 
the three hallmarks of psoriasis: erythema, induration and desquamation. The body is divided 
into four areas (head, trunk, upper and lower extremities), and for each area, the erythema, 
induration and desquamation scores are determined, based on a 0-4 scoring scale. This, in 
combination with the affected skin surface, leads to a numerical score which ranges from 0 to 
72. The PASI score augments with increasing disease severity, albeit non-linear. 
Since its introduction, the PASI score has been considered the gold standard196. In daily 
practice however, implementation of this scoring method as a standard in each patient is 
difficult, due to its time-consuming character. Furthermore, after years of experience with it, 
it has become clear that the PASI score is actually a slow, rough, non-sensitive and complex 
tool, with a high interobserver variability and low reproducibility197,98.The need for a simpler, 
rapid, more sensitive and reliable index has led to the development of a variety of alternative 
indices199. Several modificated PASI scores have been studied by various investigators, such as 
the Psoriasis Disability Index197, the Psoriasis Severity Index200, the Self-Administered Psoriasis 
Area and Severity Index201, the simplified PASI202 and a Psoriasis Assessment Severity Score199. 
Until now, none of them has replaced the PASI score. 
Traditionally, measures of severity of psoriasis have concentrated on physical measures, 
as those mentioned above. Recently, a whole newdirection in health careassessment of psoriasis 
patients has been described as the "outcomes movement". The emphasis of these assessments 
is on patient's own judgments with respect to their quality of lifes and functional capacity, 
rather than on objective physical or laboratory parameters203. However, as there is considerable 
discordance between the severity of physical disease and the degree of psychologic distress, 
objective severity scores and qualtity of life assessments provide complementary information. 
In an attempt to combine the objective severity parameters with subjective factors as indicated 
by patients themselves, new assessment tools are currently under development. The Salford 
Psoriasis Index (SPI) was designed to combine scores of the clinical extent of psoriasis, psoriasis-
induced "psychosocial disability"and historical disease severity ("interventions")204. 
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1.4.2 Physician's Global Assessment (PGA) 
This is another key measure in clinical trials, which is easier to perform and less time-consuming 
than the PASI score. Global assessments are suitable for localised plaques as well as for extensive 
disease. The static form is a reflection of the physicians estimation of disease severity at a single 
point in time, in the dynamic form the global improvement from baseline is assessed.The static 
PGA has become the standard, in particular for registration purposes in the USA. 
1.4.3 Target lesion assessments 
In target lesion assessments, the three hallmarks of psoriasis: induration, erythema and 
desquamation are being evaluated, similar to the PASI score. For each sign, a score ranging 
from 0 to 4 is given, and the total sum for all three parameters is the target lesion score. In these 
scores, one specific lesion is evaluated at different points in time, in order to evaluate the effect 
of therapy. No attention is paid to the total body surface area that is affected. This method of 
scoring psoriasis is therefore most suitable for localised psoriasis, and for evaluation of topical 
therapies205. 
V Outlines and objectives 
In this thesis we have focused on the peripheral blood T-cells in psoriasis. The motivation for 
this selective research approach is the introduction of T-cell selective therapeutic approaches 
which prove to be effective in psoriasis. Inspired by this practical issue we tried to gain a broader 
understanding of the T-cell subsets crucially involved in the pathogenesis of psoriasis. 
The aim of this thesis was to make a characterization of circulating T-cell subsets relevant 
for psoriasis in order to obtain insight in: 
(1) The contribution of peripheral blood T-cell subsets to the pathogenesis of psoriasis 
(2) The role of circulating T-cell subsets as a target for anti-psoriatic treatments 
(3) The effects of T-cell targeting treatments on some safety parameters 
We focused on a predetermined panel of T-cell markers, all of which have been described in 




The contribution of peripheral blood T-cell subsets to the pathogenesis of psoriasis 
The following questions were addressed: 
1.1 Are the numbers of peripheral blood T-cell subsets abnormal in psoriasis? 
1.2 What is the relationship between the severity of psoriasis and the number of specific 
circulating T-cell subsets? 
The role of circulating T-cell subsets as a target for anti-psoriatic treatments 
With respect to T-cells in the context of therapeutic interventions we focused on addressing 
the following question: 
To what extent do systemic immunomodulatory treatments with different mechanisms 
of action modulate the spectrum of pathogenetical relevant systemic T-cell subsets in 
psoriasis? 
The effects of T-cell targeting treatments on some safety parameters 
Effects of T-cell targeted treatments may have an impact on safety. Therefore, the following 
question was formulated: 
Does anti-TNFa treatment modulate the number of T-cell subsets in peripheral blood, 
and to what extent do these modulations interfere with safety? 
VI Investigational approach 
Lymphocytes are a subgroup of white blood cells, which are part of the cellular immune 
system. Each lymphocyte expresses on its surface membrane specific antigens, which are 
unique for that specific celltype. Each antigen that is expressed on the surface membrane 
of a lymphocyte gives the cell a specific characterization, which tells us something about its 
function. The lymphocyte surface membrane phenotype analysis, or immunophenotyping, is 
frequently used to quantify and qualify cells in several diseases, often to gain insight in the 
pathogenesis of these diseases. Immunophenotyping can also be used to monitor the effects 
of therapy, or for safety purposes. 
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1.6.1 Flow cytometry204 207 
Flow cytometry is a method to differentiate and count cells and microparticles Cells in 
suspension are passing a cuvette in a narrow stream The sensitive interaction zone is the 
interception between the sample stream and a focused light beam (laser) or electrical field 
Optical or electrical signals are sequentially generated by each single particle Signals are 
detected and displayed for cell distribution analysis 
The most important feature of flow cytometric analysis that large numbers of particles 
can be analysed m a relatively short amount of time 
Flow cytometers take advantage of laminar flow conditions in capillary tubes Cell 
suspensions are injected into a flow channel where a carrier fluid (sheath fluid) surrounds the 
cells Sheath fluid draws the cell suspension to a thin line so that cells are lined up m a narrow 
laminar Ime This is called hydrodynamic focusing The fluids (sheath fluid with centered 
sample flow) enter a flow cuvette channel (flow cell, made out of quartz glass) where they are 
illuminated The flow velocity is in the range of meters per second which results in a stable 
laminar flow condition and a high event rate (up to several thousands of cells per second) 
Laser and lamp beams are directed through the quartz cuvette Cells pass the analysis point 
(focus) where they are illuminated The light is scattered into different directions depending on 
the refractive index, size and shape of each particle Light scattered in small angles of the laser 
beam (forward scatter, FSC) indicates the particle size Scattered light which is collected m a 
cone in the orthogonal direction of the laser beam is called side scatter (SSC) It indicates size 
as well, but is influenced by surface and internal structures, mainly 
Fluorescence analysis means detecting fluorescent probes or autofluorescent 
components on the surface membranes or within the cells Depending on the staining 
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CHAPTER 2 
Summary 
Background In several studies peripheral blood T-cells have been 
quantified, yet few data are available on T-cell subsets in moderate-
to-severe psoriasis (in terms of extent and activity of lesions) versus 
mild psoriasis. 
Objective To compare lymphocyte subsets in peripheral blood 
of patients with moderate-to-severe disease (PASI-score > 12) to 
patients with mild disease (PASI-score < 12) and to healthy subjects. 
Methods By means of flow cytometry, lymphocytes in 
peripheral blood of 27 patients with psoriasis and 10 healthy controls 
were characterized. 
Results The absolute number of total lymphocytes was 
markedly decreased in patients with moderate-to-severe psoriasis 
as compared to patients with mild disease and normal subjects. 
Cellcounts of all analysed subsets were found to be increased in more 
severe psoriasis, except for CD8+CD45RO+ cells. 
Conclusion The under-representation of CD8+CD45RO+ 
cells is compatible with the dynamics of acquired immunity, which 
requires a time log after the relapse of the lesions to differentiate 
from CD45RA+ naive cells. 
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Introduction 
Psoriasis is a common inflammatory skin disease characterized by hyperproliferation of 
keratinocytes. It is a well established fact that T-cells play an important role in the pathogenesis 
of psoriasis'2. Indeed, treatments such as anti-CD43 5, anti-CD113 6 and anti-CD25 6, targeting 
at specific T-cells, have shown to be effective in psoriasis. Several T-cell subsets seem to play 
a primary role. Major classes are CD4+, CD8+, CD45RO+ and CD45RA+ T-cells. Recently, NK-T-
cells have been suggested to play an additional role in the regulation of immunity, through 
the release of cytokines79. NK-T-cells are cells bearing both T-cell receptors as well as natural 
killer-cell specific receptors such as CD161. It has been shown that circulating NK-T-cells are 
significantly reduced in some autoimmune diseases1011. 
The large body of research on the role of T-cells in psoriasis has been focused on lesionai 
T-cells.This has resulted in the hypothesis that there is a final common pathway responsible for 
the development of chronic plaque psoriasis, which may involve specific antigen recognition 
by T-cells that results in stimulation of keratinocyte proliferation. In psoriasis, CD4-I- cells seem 
to be important mainly in the early phase of plaque development. These cells are found 
predominantly in the upper dermis, whereas CD8+ cells have proven to be relevant during 
chronic phases and are found predominantly in the epidermis12, although others have found 
a more early involvement of CD8+ T-cells in the development of psoriatic plaques13. Large 
numbers of activated T-cells have been shown in clinically involved skin of psoriatic patients, 
but also uninvolved skin contains a significant number of T-cells. In healthy skin, however, 
T-cells can hardly be found. It has been suggested that circulating T-cells are activated and 
subsequently recruited from the circulation during the development of psoriatic plaques"115. 
Several studies have investigated peripheral blood T-cells of psoriatic patients7 β 12 " 1 9 . 
These studies indicated that the total amount of T-cells in patients is comparable or slightly 
increased as compared to that found in normal subjects. No relevant differences have been 
shown with respect to total T-cell counts and T-cell subsets including CD4-I-, CD8+, CD45RO+ 
and CD45RA+ cell counts. Only few studies comprise a comparison between mild and more 
severe forms of psoriasis, using clinical severity indicators such as the Psoriasis Area and 
Severity Index (PASI-score)20 21. 
The present study compares specific circulating lymphocyte subsets in patients with 
mild psoriasis, patients with moderate-to-severe psoriasis and normal subjects. 
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Materials and Methods 
Patients and controls 
Fifteen patients with moderate-to-severe psoriasis vulgaris (12 male and 3 female aged 19-66, 
mean age 46,2 years) and twelve patients with mild psoriasis (7 male and 5 female, aged 34-72, 
mean age 52,8 years) from our outpatient department participated in this study. Mean PASI-
scores in both groups were 20,97 ± 2,55 (mean ± SEM) and 6,11 ±1,27 respectively. Patients 
were classified into one of both groups based on their PASI-score. We considered all patients 
with a PASI-score <12 as having a'mild', and all patients with a PASI >12 as having a'moderate-
to-severe'psoriasis 20'21. 
Patients were free of any systemic therapy for at least four weeks and did not use any 
topical therapy in the last two weeks. Peripheral blood was obtained from all subjects with 
their written informed consent. 
Control samples were collected from ten healthy volunteers without any history or signs of 
skin disease (4 male and 6 female aged 24-49, mean age 33,8 years). 
Preparation ofPBMCs 
PBMC's were isolated from heparinized blood by density centrifugation on polyester gel 
(Becton Dickinson Vacutainer™ CPT™, Franklin Lakes NJ, USA). After filtering through a 70 μιτι 
cellstrainer, cells were washed twice. 
For flow cytometry, single-cell suspensions (concentration 5 • 10s cells/ ml) were stained 
in 1% Fetal Ca If Serum in phosphate-buffered saline (PBS) at concentrations recommended by 
the manufacturer. Additionally, 450 μΙ Propidium iodide (PI) in PBS was added to each sample 
in order to exclude non-viable cells from analysis. 
The following monoclonal antibodies were used: fluorescein isothiocyanate (FITC)-
conjugated anti-CD4, FITC-conjugated anti-CD8, phycoerythrin (PE)-conjugated anti-CD4, 
PE-conjugated anti-CD8, PE-conjugated anti-CD94 and PE-conjugated anti-CD161 (all from 
Immunotech, Marseille, France), as well as FITC-conjugated anti-CD45RA (Becton Dickinson, 
San Jose CA, USA) and FITC-conjugated anti-CD45RO (DAKO, Glostrup, Danmark). 
Flowcytometric analysis 
Cells were analysed with an EPICS Elite flow cytometer (Coulter, Luton, UK), using the forward 
scatter as a discriminator. Lymphocytes were gated based on side and forward scatter 
properties. All samples were processed within 18 hours of phlebotomy. 
The following (combinations of) PE and FITC-conjugated reagents were used to determine the 
expression of each antigen or antigen combination on lymphocytes derived from peripheral 
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blood: CD4+ (marker for T-helper cells), CD8+ (marker for cytotoxic T-cells), CD45RA+ (marker 
for naive T-cells), CD45RO-I- (marker for memory T-cells), CD94+ (marker for NK-cells, T-
cells), CD161+ (marker for NK-cells, T-cells with memory phenotype), CD4-I- CD45RA+, CD4+ 
CD45RO+, CD8+ CD45RA+, CD8+ CD45RO+, CD8+ CD94+ and CD8-I-CD161 +. 
Determination of absolute numbers of lymphocytes 
Enumeration of positive cells was performed by adding Flow Count Beads (Beekman Coulter, 
Fullerton CA, USA) to the cell suspension of PBMCs. An automatic stop after a defined amount 
of beads was programmed on the flow cytometer. Absolute counts of lymphocyte subsets were 
calculated by determining the ratio of the beads to the cell population and then multiplying 
this ratio by the number of beads in the tube. Lymphocytes were gated based on side and 
forward scatter properties; analysis was performed with Verity software. 
Ratios for CD4+/CD8+ cells, CD45RO+/CD45RA+ cells, CD4+CD45RO+/CD4+CD45RA+ 
cells and CD8+CD45RO+/CD8-I-CD45RA+ cells were calculated afterwards, with data derived 
from this analysis. 
Statistical analysis 
Data-entry and analysis was performed using Statistica 6.0 software. Means and standard 
deviations were calculated for each parameter and were tested with one-way ANOVA. 
Differences were considered statistically significant at p< 0.05. 
Results 
In total, 27 patients with psoriasis and 10 normal subjects without signs or symptoms of skin 
disease were included in the present study. Table I summarizes the demographic details and 
psoriasis related characteristics of the patients with moderate-to-severe psoriasis, patients 
with mild psoriasis and normal subjects. Four out of 12 patients with mild psoriasis had shown 
Demographics Age (years) 46,2 ±3,45 52,8 ±3,49 33,8 ±3,1 
Male: female ratio 12:3 7:5 4:6 
Psoriasis related PASI score 20,97 ±2,55 6,11 ±1,27 N.A 
characteristics 
Duration (years) 16,7 ±2,7 22,2 ±2,5 N.A 
Table I: Demographic and psoriasis related characteristics of patient and subjects participating in 
the study (mean ± SEM) 
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a minimal increase in the extent of lesions; in the others the skin abnormalities were stable. 
With respect to the 15 patients with moderate-to-severe-psoriasis, 12 had an increase of the 
extent of lesions during the preceding 4 weeks, whereas the other three had been stable. 
Total cell counts 
The total amount of gated cells in peripheral blood of normal subjects was 2220 ± 301 cells μΙ'1 
(mean ± SEM).The cell-count in mild psoriasis was 1923 ± 230 cells μΙ'. In contrast, patients with 
moderate-to-severe psoriasis had cell counts of 498 ± 95 cells μΙ '. No statistically significant 
difference was observed between normal subjects and patients with mild psoriasis. However, a 
highly significant difference (p< 0,0001) was observed between mild and severe psoriasis.The 
CD4+/CD8+ ratios in all three groups were in the same range, meaning no shift occurred in the 
distribution of these subgroups of peripheral blood lymphocytes. 
The total number of lymphocytes, and the CD4+ and CD8-I- counts of the patients 
with moderate-to-severe disease were also routinely measured at the GLP certified Central 
Haematology Laboratory in our hospital, in which the whole blood lysing method is the 
standard. Comparison of both methods reveals an acceptable resemblance in results, with 
lower counts of maximum 10 percent. 
Lymphocyte subsets 
Lymphocyte subsets as a percentage of total gated cells are summarized in Figure 1. CD4+, 
CD8+, CD45RA+ and CD45RO+ cells are increased in patients with severe psoriasis as compared 
to patients with mild psoriasis and normal subjects (p<0.0001 in all cases). 
• normal subjects Oml ld psoriasis • moderate-to-severe psoriasis 
50,0 τ ; 1 
'y ι ι ι 
CDU CDS* CD45RO+ CD45RA+ 
Figure 1: CD4, CDS, CD45RO and CD45RA subpopulations, expressed as a percentage of total 
lymphocyte counts. Comparison between normal subjects, patients with mild- and patients with 
moderate-to-severe psoriasis. (*: p<0.0001) 
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No significant differences were observed between patients with mild psoriasis and 
normal subjects. 
Double labelling of lymphocytes revealed that the percentages of CD4+CD45RO+, 
CD4+CD45RA+ and CD8+CD45RA+ cells were significantly increased in moderate-to-severe 
versus mild psoriasis (p<0,001 in all cases), whereas the percentage of CD8-I-CD45RO+ cells 
was not increased significantly (figure 2). Cell ratios for CD4+/CD8+ cells, CD45RO+/CD45RA+ 
cells, CD4CD45RO+/CD4CD45RA+ cells and CD8CD45RO+/CD8CD45RA+ cells are summarized 
in figure 3. 
anormal subjects Dmild psoriasis • moderate-to-severe psoriasis 
20.0 τ 
il ι - I 
CD4+CD45RO+ CD4+CD45RA+ CD8+CD45RO+ CDe+CD45RA+ 
Figure 2: Expression of CD4-I-CD45RO+, CD4CD45RA+, CD8+CD45RO+ and CD8CD45RA+ cells, as 
percentage of the total amount of lymphocytes, in three subgroups: moderate-to-severe psoriasis, 
mild psoriasis and normal subjects {*: p<0.001) 
I Onormal subjects Omlld psoriasis • moderate-to-severe psoriasis 
2.5 τ ι 
' π I ^É Γι ^ 
o.o J 1 L — „ „ ^ 1 j 1 ^ 1 1 1 fl^^B 1 1 1 ^ 
CD4t/CD8t CD45ROWCD45RA+ CD4+CD45RO*/CD4+CD45RAt CDe*CD45RO+/CD8tCD45RA* 
Figure3: RatiosofCD4/CD8,CD45RO+/CD45RA+,CD4CD45RO+/CD4CD45RA+and CD8CD45RO+/ 
CD8CD45RA-I- in normal subjects, mild and moderate-to-severe psoriasis (*: p<0.05) 
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T-ce/Zs expressing Ν Κ cell receptors 
CD94+ and CD161+ cells, expressed as a percentage of total cells were increased in patients 
with moderate-to-severe psoriasis, as compared to patients with mild psoriasis and normal 
subjects (p<0.05 and p< 0.001 respectively). Figure 4 summarizes these observations. Again no 
statistically significant differences were observed between normal subjects and patients with 
a mild form of psoriasis. 
With respect to double stained cells, we observed an increase in the expression of both 
CD8+CD94+ cells as well as CD8+CD161 + cells (markers for NKΤ subpopulations) in patients 
with a more extensive form of psoriasis, expressed as a percentage of the total amount of 
cells, as compared to patients with mild psoriasis and normal subjects (p< 0,008 and p<0,009 
respectively, results shown in figure 5). 







^ ^ ^ 
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Wm~ 
τ 
Figure 4: CD94 and CD161 subpopulations, expressed as a percentage of total lymphocyte counts. 
Comparison between normal subjects, patients with mild- and patients with moderate-to-severe 










Figure 5: Cellcounts of CD8+CD94+ and CDS+CDI61+ cells as percentage of total lymphocytes (* 
p<0.009) 
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Correlation between PASI-score and lymphocyte subsets and cells expressing NK 
receptors 
Linear regression analysis revealed no significant correlation between the individual 
PASI-scores and the quantifications of lymphocyte subsets or cells with NK-cell receptors 
Correlation analysis between disease activity and peripheral lymphocytes did not reveal a 
difference between patients with spreading lesions and those with stable plaque psoriasis 
Discussion 
The results of this study show marked differences in absolute cellcounts between the three 
patient groups Our mam goal was to investigate whether there is a difference m the occurrence 
of biomarkers on circulating lymphocytes m mild psoriasis versus more severe forms of the 
disease One of the criteria to qualify for a treatment with major systemic therapies such as a 
biological often is a minimum PASI-score of 12 20 2i We were interested whether this cut-off 
point also implies a differentiation between mild versus moderate/severe psoriasis in terms of 
T-cell and NKT-cell subsets The results of the present study have shown us, there are indeed 
marked differences between mild psoriasis and the more severe forms of disease defined by 
cut-off point PAS112 
A decrease of total lymphocyte counts, as percentage of PBMC, and an increase in the 
percentage of CD4-I-CD45RO+ cells in patients with moderate-to-severe psoriasis has been 
reported before u These patients (32 subjects) had an average PASI of 25,7 (10-48), and all 
had had an exacerbation following infection Patients had a mixed morphology, from guttata 
psoriasis to chronic plaque psoriasis In the same study, however, a decrease m the amount of 
CD4-I- cells was described, which is in contrast with the findings in our study Other authors 
have reported no significant difference m total T-cells as percentage of PBMC counts between 
patients with psoriasis and normal subjects 7 These patients (14 subjects) had an average 
PASI of 23,5 ± 10,6 However, no information was given whether these patients had relapsing 
psoriasis In the present study, the patients with severe psoriasis had an extension of lesions 
during the wash out period (average increase m PASI 4,9) Therefore, the severity m our patients 
not only comprises the extent of lesions but also activity of lesions with progression and 
therefore approaches the characteristics of the patients reported by Lecewicz et al, who also 
reported a decrease of T-cells m peripheral blood m psoriasis (expressed as percentage of total 
PBMC) The decrease of lymphocyte counts, expressed as a percentage, in peripheral blood m 
patients with moderate-to severe psoriasis is the reverse of the substantial accumulation of 
lymphocytes m psoriatic skin The most likely explanation for this paradox is an increased influx 
of cells into the skin of patients with severe disease Further studies, m which simultaneous 
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measurements of lesionai and circulating T-cells will be performed, need to be carried out to 
support this hypothesis 
A striking observation is the increased percentage of both CD4+ cells and CD8+ cells in 
patients with moderate-to-severe psoriasis as compared to mild psoriasis and normal subjects, 
without a change m CD4/CD8 ratio. So far, reports on the CD4+/CD8+ ratio in psoriasis have 
been at variance1'' " 
With respect to the double labelled lymphocytes, both the percentage of CD4+CD45RO+ 
cells as well as the percentage of CD4+CD45RA-I- cells is increased in patients with moderate-
to-severe psoriasis, m contrast to the absolute decrease of total lymphocytes.The relative count 
of both subsets is increased, whereas their ratio shows a tendency to decrease (p=0 0509). 
Thus, with increasing severity of disease, the increase m CD4-I-CD45RA+ cells seems to exceed 
the increase m CD4+CD45RO+ cells An explanation for this phenomenon is the preferential 
migration of CD4+CD45RO+ cells into lesionai skin in extensive disease, resulting in a relative 
decrease of this subset of CD4+ lymphocytes in peripheral blood This hypothesis supports 
earlier studies where CD4+CD45RO+ cells have been shown to be the major players in 
psoriatic plaques Indeed, CD4-I- cells appear in a very early phase of the psoriatic process. In a 
previous study CD4-I- cells have been detected in the distant unmvolved skin of patients with 
active psoriasis13 The percentage of CD8-I-CD45RO-I- cells m patients with moderate-to-severe 
psoriasis approached the percentages m patients with mild psoriasis and normal subjects, 
m contrast with the CD8+CD45RA+ cells, which did show a significant increase in peripheral 
blood. The impressive under-representation of CD8-I-CD45RO+ lymphocytes as compared to 
CD8-I-CD45RA+ lymphocytes in moderate to severe psoriasis suggests a preferential influx of 
CD8+CD45RO-I- cells into the skin Both CD8-1- cells, as well as CD45RO+ cells are abundantly 
present m psoriatic lesionai skin. Previously we have shown that in the outer margin of the 
spreading psoriatic plaque the number of CD8+ cells and CD45RO+ cells were increased13. 
Therefore, the relative under-representation m peripheral blood of CD45RO+ cells, in particular 
the CD8+ CD45RO+ cells, most likely reflect the influx of these cells into the skin in patients 
with moderate-to-severe psoriasis m an active phase of disease However, further studies 
are needed to support this hypothesis Lymphocyte counts, preferably T-cells, in skin as well 
as in the peripheral blood should be monitored during a longer period of time, e.g. during 
exacerbation and during disease-free intervals. The CD8+CD94-I- cells and CD8+CDI6I-1- cells 
show a marked increase in patients with moderate-to-severe psoriasis as compared to mild 
psoriasis and normal subjects The increases of these lymphocytes expressing NK receptors in 
peripheral blood are accompanied with increases of these cells m the psoriatic lesion. 
The results of the present study suggest that m peripheral blood of patients with 
moderate-to-severe psoriasis, m contrast to the vast presence of T-cells m skin lesions, the 
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absolute T-cell counts are profoundly decreased, without any change of CD4/CD8 ratio. The 
relative under-representation of CD45RO+ cells, as compared to CD45RA+ cells, in peripheral 
blood most likely results from a massive influx of memory effector T-cells into the psoriatic 
lesions in an active phase of disease. Both in blood and skin of patients with moderate-to-
severe psoriasis the percentages of CD94+ and CDI6I-1- cells are increased. These results are 
compatible with the functions of these cells. CD45RO+ cells differentiate from CD45RA+ cells 
and represent acquired immunity, whereas NK-T-cells are able to act without prior sensitization, 
representing innate immunity.7 In further research, more selective T-cell markers are required 
in order to investigate the role of peripheral blood T-cells in the pathogenesis of psoriasis, and 
correlation studies between peripheral blood T-cells and T-cells in skin are required in order to 
understand the dynamics of compartmentalization of T-cell subsets belonging to either the 
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CHAPTER 2 
Abstract 
Background Psoriasis has been suggested to be a T-cell mediated 
disease. Activated lymphocytes are present in skin and blood 
of psoriatic patients. Several treatments targeting T-cells have 
favourable effects in psoriasis. More therapies with either direct or 
Indirect effects on T-cells are currently under development. 
Aim: To obtain insight in T-cell dynamics, as baseline 
information regarding absolute T-cell numbers in different disease 
stages is needed. 
Method We included 40 psoriasis patients with Psoriasis 
Area and Severity Index scores ranging from 1,6 to 39,7. They were 
subdivided Into three groups, based on severity of disease. Peripheral 
Blood Mononuclear Cells (PBMC) were obtained and the numbers 
of cells expressing the following (combinations of) markers were 
measured by means of flowcytometry: CD4, CDS, CD45RA, CD45RO, 
CD94, CD161, CD25 and CLA. 
Results Cellcounts for almost all subsets where significantly 
higher in the group of moderate psoriasis patients as compared to the 
mild psoriasis patients. In patients with a PASI score > 20, cellcounts 
decreased as compared with moderate psoriasis. 
Conclusion The depletion of circulating T-cells In severe 
psoriasis probably Is the result of extravasation of cells to the site of 
Inflammation. During the period preceding this migration, activated 
cells first proliferate In the systemic compartment, explaining the 
Increased cell numbers in the group of moderate psoriasis patients. 
This discrepancy between PASI score and T-cell counts can be 
misleading as It comes to determining the right moment to start 
biological therapy. 
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Introduction 
There is growing evidence that activated T-cells are the primary modulators in the pathogenesis 
of psoriasis. This is supported by the fact that increased levels of activated lymphocytes are 
present in psoriatic skin plaques and blood of patients1. Furthermore, treatments targeting 
specific T-cells have shown to be effective in psoriasis2 5. 
Although T-cells form only one constituent of the complex mechanism which is 
responsible for the development of the characterizing scaling hyperplastic plaques in psoriasis6, 
an extensive number of studies focusing on the T-cell has been published. Subsets of T-cells 
which have been suggested to play a key role in psoriasis are CD45RO+7, CD25+3, HLA-DR+8, 
CD27+9 and cutaneous lymphocyte antigen CLA10". Most of them are activated memory T-
cell phenotypes, which can either be CD4+ or CD8+. More recently, a role was attributed to a 
group of T-cells expressing Natural Killer (NK) receptors (CD94, CD161 ) as well12. Changes in the 
number or functionality of NKT-cells have been described in relation to autoimmune or chronic 
inflammatory diseases13. The recent insights in the pathogenesis of psoriasis have led to the 
development of more selective therapeutics, the so-called biologies. They have the capability 
to interfere with the immune system, in four possible ways: reduction or elimination of T-cells, 
prevention of intracellular interactions, inducing immune deviation fromThl towards Th2, or 
inactivation of cytokines14. They have a selective effect on the immune system, in contrast with 
the established antipsoriatic therapies, such as cyclosporine and methotrexate, which have a 
broad impact on immunity. However, a limitation of biologicals selectively targeting theT-cell, 
such as alefacept and efalizumab, is their capacity to (almost) clear psoriasis, which has been 
reported to be 28%15 and 13%16 respectively. 
To obtain more insight in the dynamics of T-cells in psoriasis, it is necessary to have 
information on baseline values of T-cells in different degrees of disease severity. As the data up 
to now are still controversial, we designed a study in which we compare T-cell counts in three 
different degrees of severity of psoriasis. 
Patients and methods 
For this study we included 40 patients with Psoriasis Area and Severity Index scores ranging 
from 1,6 to 39,7. Twenty-six of them were male, fourteen female. Ages ranged from 19 to 78, 
with a mean age of 48 ± years (mean ± SEM). A wash out period of two weeks was required for 
topical therapies, four weeks for systemic treatments. During washout, no significant changes 
in PASI-score occurred. All participating psoriatic patients were otherwise healthy and did not 
suffer from clinically relevant infections in the past three months, nor from psoriatic arthritis. 
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Patients were Informed both verbally and in writ ing. They all signed Informed consent forms 
prior to any study-related procedure. Approval for this study was given by the Medical Ethical 
Board of the Radboud University Nijmegen Medical Centre. 
The data for each specific subset of T-cells were first analysed individually In order to find 
a correlation between disease severity and the circulating lymphocytes. We secondly divided 
our patients in three subcategories: group A (mild psoriasis, PASk 12), group Β (moderate 
psoriasis, PAS112-20) and group C (severe psoriasis, PASI>20). The number of patients in group 
A was 12, In group Β 15 and group C 13 patients. Clinical observations as erythema, induration, 
scaling and affected area were all noted separately as well as in the PASI score. 
Cell preparation 
From each patient, 10 ml blood was obtained by means of a venepunction from the arm. 
Samples were processed as soon as possible. Time between blood withdrawal and analysis 
never exceeded 24 hours. Processing of samples was performed by the same person In all 40 
cases. Peripheral Blood Mononuclear Cells (PBMC) were Isolated from the whole blood samples 
by density centrlfugatlon on polyester gel (Becton Dickinson Vacutainer'TPT'", Franklin Lakes 
NJ, USA). After washing the cells twice, the single-cell suspensions with a concentration of 5 χ 
10E5/ml were stained using either Fluorescln isothlocyanate (FITC)-conjugated or Phycoerythrln 
(PE)-conjugated monoclonal antibodies (table I), or combinations of them. Propidlum Iodide 
was used as a marker for non-viable cells, which were excluded from analysis. 
Cell counts 
Each single-cell suspension was stained with a combination of monoclonal antibodies to 
determine the expression of the following (combinations of) T-cell markers: CD4 (T helper 
cells), CDS (cytotoxic T-cells), CD45RA (naive Τ lymphocytes), CD45RO (memory T-cells), 
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CD94 (NK cells, T-cells), CD161(NK cells, T-cells with memory phenotype), CD25 (IL2 receptor, 
activation marker), CLA (cutaneous lymphocyte antigen, skin homing receptor), CD4CD45RA, 
CD4CD45RO, CD8CD45RA, CD8CD45RO, CD8CD94, CD8CD161, CD4CD25, CD4CLA and 
CD8CLA 
Cells were analysed with a Coulter Elite Flow Cytometer Enumeration of positive cells 
was facilitated by the use of Flow Count Beads (Beekman Coulter, Fullerton CA, USA) An 
automatic stop was programmed after a defined amount of beads, whereafter the ratio beads 
cell population, and thus absolute lymphocyte numbers could be determined 
Statistical analysis 
Data-analysis was performed using Statistica 6 0 software Means and standard errors of mean 
were calculated for each parameter and an analysis of variance was performed Differences 
were considered statistically significant at p<0 05 
Results 
The mean PASI score of all 40 patients was 16 ± 1,5 (mean ± SEM) Baseline counts were made 
for each aforementioned cell marker and for several specific combinations of cell markers 
as well 
The mean PASI scores of the three groups m which the participating patients were 
subdivided were 6,3 in group A, 15,5 in group Β and 28,4 m group C In figures 1 to 4 the data 
for the different cellmarkers are depicted for groups A (PASI <12), Β (PASI 12-20) and group C 
(PASI >20) 
Analysis of the individual patient data did not show any evident correlations between 
lymphocyte subsets and disease severity (data not shown) However, subdividing the patients 
m three groups based on disease severity reveals some important differences 
CD4+andCD8+ 
The number of cells expressing either CD4 or CD8 significantly augments when comparing 
mild (group A) with moderate (group B) psoriasis (p< 0 05) Yet comparing moderate psoriasis 
with severe psoriasis, shows us a decrease m CD4-I- and CD8+ cellcounts with climbing PASI 
score 
Activation markers 
The mean cellcounts of T-cells expressing CD45RO+, CD4CD45RO+ and CD8CD45RO+ in 












DGroupA(PASI<12) BGroup Β (FAS112-20) DGroup C (PAS! >20) 
Figure 1: Absolute cellcounts in cells/mm3 of CD4+, CD8+, CD45RO+ and CD45RA+ cells in mild, 
moderate and severe psoriasis (* ρ <0.05 as compared to group A, ** ρ <0.05 as compared to 
group B) 
aCroupAiPASI <12) BGroup Β (PASI 12-20) BGroup C {PASI >20) 
Figure 2: Expression of CD94+, CD161+, CD25+ and CLA+ cell markers in three disease stages of 
psoriasis (* ρ <0.05 as compared to group A, ** ρ <0.05 as compared to group B) 
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CD4+CD45no* CD4+CD45Ra+ CD8+CD45RO+ CD8tC045Ra+ 
• GroupA(PASI<12) • Group Β (PASM2-20) mGroupC (PASI >20) 
Figure3: Comparison of absolute cell numbers of CD4CD45RO+,CD4CD45RA+,CD8CD45RO+and 
CD8CD45RA+ in mild, moderate and severe psoriasis (* ρ <0.05 as compared to group A, ** ρ <0.05 
as compared to group B) 
• GroupA|PASI<12) • Group Β (PASM 2-201 BGroupC(PASI>20) 
Figure 4: Absolute cell numbers for CD8CD94+, CD8CD161+, CD4CD25+, CD4CLA+ and CD8CLA+ 
subpopulations of lymphocytes in mild, moderate and severe psoriasis {* ρ <0.05 as compared to 
group A, ** ρ <0.05 as compared to group B) 
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group of patients with severe psoriasis, the activated celltypes have decreased again to a 
value comparable with that of mild psoriasis patients. With respect to the activation marker 
CD25, no differences were found between expression mild psoriasis as compared to moderate 
psoriasis. 
Cells expressing NK receptors 
With regard to the CD94+, CD161+, CD8CD94+ and CD8CD161+ subpopulations, differences 
between mild, moderate and severe psoriasis are seen as well. The number of CD94+ cells is 
the same in group A and group B, and they show a decrease only when PASI-score exceeds 20 
(group C). The same pattern isseenfortheCD8CD94+ subpopulation. With regard to CD161 + 
and CD8CD161 + cells, these show an obvious increase in group Β as compared to group A (non­
significant), with cell numbers diminishing even below baseline values in group C (p<0.05). 
Cutaneous lymphocyte antigen 
The skin-homing CLA+ cells, are increased in moderate psoriasis when compared to mild 
psoriasis. In severe psoriasis, the cell numbers of these subsets are comparable with that of 
mild psoriatic patients. As far as the double stained populations CD4+CLA+ and CD8+CLA+ 
concerns, these show a reduction in moderate psoriasis as compared to mild psoriasis. In 
severe psoriasis, CD4+CLA+ cellcount decreases slightly more, the CD8+CLA+ count remains 
stable as compared with moderate psoriasis. 
In conclusion, it is shown that most subsets of lymphocytes show a consistent relation 
to disease severity: CD4+ and CD8+ cells and cells expressing the activation marker CD45RO 
are increased in moderate psoriasis as compared to mild disease, whereas the numbers of skin-
homing T-cells are decreased in moderate and severe psoriasis. 
Discussion 
Based on the results shown above, it is conceivable that peripheral blood T-lymphocytes have 
a typical pattern dependent on the disease severity. When PASI score is low, little activated 
T-cells can be found in peripheral blood. With increasing PASI score, more T-cells become 
activated, probably triggered by the inflammatory processes in the skin, leading to increased 
circulating cell counts in moderate psoriasis. These activated T-cells start their migration to 
the skin, however not yet to the extent that they cause depletion in peripheral blood. When 
skin symptoms become very severe, we see decreasing circulating T-cell numbers. This could 
be explained by a more extensive migration of T-cells, into the lesionai skin. In the case of 
CLA+ cells, which in contrast with the other cell types, are decreased in moderate psoriasis, 
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this migration probably commences in a much earlier stage of disease activity Results on 
the role of cell expressing the NK cell marker CD94 are so far still controversial A decrease of 
this cell type in psoriasis has been described before by Cameron et al ' 7 , a finding which is m 
concordance with findings on NK cells m autoimmune diseases A more recent study by Liao 
et al however shows a PASI-related increase of CD8+CD94+ cells, suggesting chronic antigen-
driven stimulation19 As NK T-cells are known to have multiple functions, their exact role in the 
pathogenesis of psoriasis still requires further investigations 
So far, it is not clear to what extent peripheral blood T-cells and resident T-cells serve 
as a target for anti-psonatic treatments Resident T-cells are of relevant importance m the 
pathogenesis of psoriasis the course of psoriatic skin involvement and psoriatic arthritis in the 
same patient is independent, suggesting tissue-related pathogenetic factors On the other 
hand, bone marrow transplants have shown that systemic bone derived cells may either elicit 
or cure psoriasis1920 This clinical observation suggests that peripheral blood Τ cells may act as 
a therapeutic target 
Following the supposition that blood derived T-cells are of importance in the 
pathogenesis of psoriasis, it can be hypothesized that the increase in numbers of peripheral 
blood T-cells in moderate psoriasis as compared to mild disease indicates a major contribution 
for systemic therapies in the treatment of moderate disease However, in more severe diseaseT 
cell targeted treatments may be incapacitated for reason that the activated peripheral blood T-
cells have shifted into the skin The treatment paradigm to withhold T-cell directed treatments 
from patients with moderate disease and to provide them to patients with severe involvement 
is therefore at variance with the pathophysiology of the disease with less peripheral blood T-
cells in severe disease 
The present study is an extension of a previous investigation from our centre, in which 
we compared percentages of specific lymphocyte subsets in peripheral blood of healthy 
subjects with those of mild psoriatic and moderate psoriatic patients (cut-off point PASI 
12) Our mam goal was to investigate if there are differences m the occurrence of specific 
biomarkers in psoriasis as compared to healthy controls We found increases in the populations 
of CD4+, CD8+, CD45RO+, CD45RA+, CD94+, CD!61+, CD4CD45RO+, CD4CD45RA+, 
CD8CD45RA+, CD8CD94+ and CD8CD161+ (expressed as a percentage of total cells) with 
decreasing CD4CD45RO/CD4CD45RA and CD8CD45RO/CD8CD45RA ratios in moderate-to-
severe psoriasis (PASI > 12) as compared to normal subjects and mild psoriasis (PASI <12) The 
relative under-representation of CD45RO+ cells suggests a preferential influx of these cells 
into the skin A major role for CD45RO+ cells in evolving psoriatic plaques has been described 
before21 However, as various patients in our previous study experienced an increase in PASI-
score during the wash out period for topical and systemic therapies, it could not be confirmed 
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whether the observed differences m expression are the result of differences m disease severity 
rather than the changes in disease activity" With this current investigation, in which psoriasis 
was stable in all patients, we are able to reconfirm most of our earlier findings 
The interpretation of individual T-cell counts remains difficult however, as they can 
diverge enormously between individuals, and are dependent on a variety of factors, such as 
age, gender, infections, chronic fatigue and even stress This could possibly be an explanation 
for the fact that we were not able to find a clear correlation between disease severity and 
individual lymphocyte counts However, when grouped, clear differences are seen between 
mild, moderate and severe psoriasis with respect toT cell counts, indicating a linear relationship 
between clinical severity and T-cell counts from mild to moderate psoriasis and, in contrast, an 
inverse relationship from moderate to severe disease 
In most dermatological practices, one is used to apply systemic therapies only when 
all possible local treatments for psoriasis have been tried, and/or the psoriasis is really severe 
Considering the aforementioned hypothesis, this could be too late T-cells have migrated to 
the skin and are therefore not an appropriate target anymore Intervention should preferably 
take place just when the number of circulating T-cells reaches a maximum, and our results 
show this is not necessarily when PASI score is at its maximum 
The current policy with regard to the prescription of biological treatments for psoriatic patients 
focuses very much on safety issues Perhaps this is one of the mam reasons why biologicals are 
only one of the last steps in the treatment of psoriasis Because the long term side effects 
of most of the biologic treatments are unknown, physicians tend to be precautious when it 
comes to prescribing biologicals 
The depletion of circulating T-cells m severe psoriasis probably is the result of 
extravasation of cells to the site of inflammation During the period preceding this migration, 
activated cells first proliferate m the systemic compartment, explaining the increased cell 
numbers in the group of moderate psoriasis patients This discrepancy between PASI score and 
T-cell counts can be misleading as it comes to determining the right moment to start biological 
therapy 
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Abstract 
Fumarie acid esters (FAE) have been proven to be effective in the 
systemic treatment of psoriasis vulgaris. Its exact mechanism of 
action is still not fully understood. One of the modes of action 
is thought to be an inhibition of T-cell activation, indicating an 
immunosuppressive effect. Currently, one of the main components of 
the marketed FAE-mixture, dimethylfumarate, is under investigation 
as a monotherapy. 
The aim of the present study is to determine the effect of a 
16-week treatment with dimethylfumarate on circulating numbers of 
T-cells expressing CD4, CD8, CD45RO, CD45RA, CD94, CD161, CD25, 
CLA or combinations of these cell markers, as compared to placebo. 
Ten patients with moderate-to-severe psoriasis (PASI>12) 
were included in this study and randomized to receive either 3x2 
capsules of 120 mg dimethylfumarate per day, or placebo. Peripheral 
blood was obtained in 6 patients before and after 16 weeks of 
therapy. T-cell subsets were analysed by means of flow cytometry. 
Enumeration of cells showed a significant decrease in 
absolute circulating numbers of CD4+, CD45RO+, CD4-I-CD45RO+, 
CD4+CD25+andCD4+CLA+T-cellsaftera 16-week treatment course 
with dimethylfumarate, whereas the cellcounts of the CD8+ and 
CD45RA-I- populations remained stable. In the control group, no 
changes in circulating lymphocyte subsets were found. 
Dimethylfumarate as a monotherapy has a suppressive effect 
on various lymphocyte subpopulations, which have a pathogenetic 
relevance. Its effect seems to be mainly directed against the CD4+ 
and CD45RO+ populations of T-cells, without influencing the CD8+ 
and CD45RA+ populations. This implies a selective inhibition of 
activated T-cells. 
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Introduction 
Fumane acid esters (FAE) have been used m the treatment of psoriasis for over 40 years 
and have been proven to be effective'4 Because controversy on its safety profile exists, 
dermatologists tend to be careful in prescribing this medication to their patients5 The 
incidence of negative side-effects is reported to be up to 73%3. Frequently occurmg adverse 
effects are flushing, gastrointestinal complaints and lymphopenia2 Adverse events reported 
were dose-dependent and decreased in frequency as patients proceeded with their therapy. 
Nevertheless, they often are reason for early discontinuation of therapy and, in addition, give 
rise to high non-compliance rates6. 
In the past, studies have been conducted to investigate the therapeutic properties of 
the different FAE. Both monoethylfumarates (MEF) and dimethylfumarate (DMF) alone were 
tested, as well as a combination of both.The DMF/MEF combination proved to have the most 
favourable clinical effect7. This eventually led to the legislation of a defined mixture of FAE m 
Germany, in 1994 (Fumaderm®, Fumapharm AG, Muri Switzerland) Recently, renewed clinical 
studies with the most potent ingredient of Fumaderm, dimethylfumarate, were initiated. 
Theories on the exact mechanism of action of FAE changed through the years. It was first 
thought that psoriasis was the result of an endogenous deficiency of fumarie acid, an active 
metabolite of the citric acid cycle This idea changed in the theory that a disturbed citric acid 
cycle played an important role in the pathogenesis of the disease. Currently, the favourable 
effect of FAE m psoriasis is thought to be the result of immunomodulation Numerous m vitro 
effects of DMF on the immune system have been described apoptosis of T-cells, shifting a 
Thl -mediated immunorespons towards a Th2-mediated respons by induction of synthesis of 
anti-inflammatory cytokines289 and downregulation of expression of several chemokmes910 
It has also been shown that DMF is capable of inhibition of keratmocyte proliferation m 
vitro"12. Furthermore, histologic and immunologic studies reported a reduction of the T-
helper cell population in psoriatic lesions after treatment with fumarates'3. 
The present study was designed to investigate the effect of dimethylfumarate on 
circulating T-cells and NK/T-cells in psoriasis in order to obtain further information on its 
suggested immunomodulatmg mechanism, and to get insight in its safety profile with regard 
to the effects on specific lymphocyte populations. 
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Patients and methods 
Patients 
Ten patients included in a double blind multicentre clinical trial to evaluate the efficacy and 
the safety of dimethylfumarate in comparison with placebo in subjects with moderate to 
severe psoriasis (protocol FAG-201-KG-01/02) were asked to participate in a parallel study 
to investigate the effect of dimethylfumarate on circulating T-cells subsets. All patients were 
above 18 years old, suffering from moderate-to-severe psoriasis, and otherwise healthy. 
Concomitant use of betablockers, lithium salts or anti-malaria agents was not allowed during 
the study. A wash-out period of two weeks for topical anti-psoriatics and UVB and a wash-out 
period of 6 weeks for systemic anti-psoriatics and PUVA was observed. 
Patients were randomized to receive either 6 capsules of 120 mg dimethylfumarate 
per day, or 6 capsules placebo, in a double-blind manner. Frequent control visits took place 
at our outpatient clinic; every two weeks during the first two months and every four weeks in 
the months thereafter. Peripheral blood for analysis of T-cell subsets was obtained at baseline 
and after 16 weeks of therapy. 
Enumeration of T-cells 
All samples were processed within 24 hours after venapunction. PBMC were isolated from 
heparinized blood by density centrifugation on polyester gel (Becton Dickinson Vacutainer™ 
CPT™, Franklin Lakes NJ, USA). After filtering through a 70 μπη cellstrainer, cells were 
washed twice. 
For flowcytometry, single-cell suspensions (concentration 5 · 105 cells/ ml) were 
stained in 1% Fetal Calf Serum in phosphate-buffered saline (PBS) at the recommended 
concentrations. To exclude non-viable cells from analysis, 450 μΙ of 5% Propidium iodide (PI) 
in PBS was added to each sample. 
We used the following panel of monoclonal antibodies in our analyses: fluorescein 
isothiocyanate (FITC)-conjugated anti-CD4, FITC-conjugated anti-CD8, FITC-conjugated anti-
CD25, phycoerythrin (PE)-conjugated anti-CD4, PE-conjugated anti-CD8, PE-conjugated 
anti-CD94 and PE-conjugated anti-CD161 (all from Immunotech, Marseille, France), as well 
as FITC-conjugated anti-CD45RA, FITC-conjugated anti-CLA (Becton Dickinson, San Jose 
CA, USA) and FITC-conjugated anti-CD45RO (DAKO, Glostrup, Danmark). These conjugated 
reagents were used, alone or in combination, to determine the expression of each antigen 
or antigen combination on lymphocytes derived from peripheral blood: CD4+ (T-helper 
cells), CD8+ (cytotoxic T-cells), CD45RA+ (naive T-cells), CD45RO+ (memory T-cells), CD94+ 
(NK-cells, T-cells), CD161+ (NK-cells, T-cells with memory phenotype), CD25+ (activated T-
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cells) and CLA+ (skin-directed T-cells). Double-labelling for CD4+ CD45RA+, CD4+ CD45RO+, 
CD8+ CD45RA+, CD8+ CD45RO+, CD8-I- CD94+, CD8+CD161+, CD4+CD25-I-, CD4+CLA+ and 
CD8+CLA+ was performed. 
Cells were analysed with a Coulter® Elite flow cytometer (Beekman Coulter Ine, 
Fullerton, USA). Lymphocytes and T-cells were gated based on side and forward scatter 
properties. Determination of absolute numbers of positive cells was facilitated by adding Flow 
Count Beads (Beekman Coulter, Fullerton CA, USA) to the cell suspension. The flowcytometer 
was programmed to automatically stop counting after a defined amount of beads. Absolute 
counts of lymphocyte subsets were calculated by determining the ratio of the beads to the 
cell population and then multiplying this ratio by the number of beads in the tube. Analysis 
was performed with Verity software. 
Ratios for CD4+/CD8+ cells, CD45RO+/CD45RA+cells, CD4+CD45RO+/CD4+CD45RA+ 
cells and CD8+CD45RO+/CD8+CD45RA+ were computed from the data derived from FACS 
analysis. 
Statistical analysis 




Informed consent was obtained from all patients. During the course of the trial, two patients 
withdrew their consent, one patient ended his participation because of an unacceptable 
adverse event and one patient switched to another anti-psoriatic therapy. Eventually, 
phenotyping of peripheral blood lymphocytes was performed in six patients. Four males and 
two females were included, ages ranging from 28 to 58 (median age 41 ). 
Unblinding of the study demonstrated three patients had been randomized to 
receive placebo (2 males, 1 female, age 45.7 + 3.9 (mean ± SEM) and the other three received 
dimethylfumarate (2 males, 1 female, age 39.3 ± 7.6. None of the patients experienced serious 
side effects during therapy, nor during the follow up period. 
Clinical effect 
The PASI-scores at baseline were 20.3 ± 4.7 (mean ± SEM) in the placebo group and 21.8 ± 
3.0 in the dimethylfumarate group. After 16 weeks of therapy the PASI-score in the placebo 
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group had increased with 11% to 22.1 ± 4.4. In patients using dimethylfumarate the PASI-
score had decreased to 10.3 ± 1.7, a statistically significant reduction of 50% (figure 1 ). 
Lymphocyte subsets 
Comparison of the absolute numbers of each specific subset of T-cells showed marked 
differences in the treatment group after 16 weeks, whereas in patients treated with placebo 
for 16 weeks no statistically significant differences were found. 
Treatment with dimethylfumarate resulted in a decrease of the mean number of 
T-cells from 4031 cells/μΙ to 1260 cells/μΙ. This is a substantial decrease of 69% (p= 0.02). 
Furthermore, patients treated with dimethylfumarate had significantly reduced absolute 
cellcounts of various T-cell subsets: CD4+ (p= 0.01), CD45RO+(p= 0.03) , CD4CD45RO+(p= 
0.03) , CD4+CD25+ (p= 0.03), CD4+CLA+(p= 0.01) . The CD8+CD45RO+ population only 
showed a tendency to decrease (p=0.06). The lowest number of CD4+ cells measured in an 
individual patient after 16 weeks of treatment was 571 cells/μΙ, which is well-above the safety 
level (figures 2-5). 
The CD4/CD8-, CD45RO/CD45RA-, CD4CD45RO/CD4CD45RA- and CD8CD45RO/ 
CD8CD45RA-ratios all showed a tendency to decrease after treatment with dimethylfumarate. 
The CD4/CD8-ratio at baseline was 3.0, after the aforementioned therapy it had decreased to 
2,0. The only significant change, as far as the calculated ratios concerns, was observed in the 
CD4CD45RO/CD4CD45RA-ratio. A 16-week treatment with dimethylfumarate resulted in a 
decrease from 2.0 at baseline to 0.56 afterwards (p=0.03). 
7"-ce//s expressing NK-receptors 
In contrast with the aforementioned subsets, which were all reduced after therapy, the CD94+ 
population had markedly increased after a 16-week treatment with dimethylfumarate (figure 
30 
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D Baseline • 16 weeks 
Figure 1: PASI scores before and after treatment with dimethylfumarate and in the placebo 
group 
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Figure 2: Cellcounts of total T-cells, CD4+, CD8+, CD45RO+ and CD45RA+ cells before and after 
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Figure 3: Cellcounts of CD94+, CD161 +, CD25+ and CLA+ cells after the 16-week treatment period 
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Figure 5: Expression of CD45RO+ and CD45RA+ on CD4+ and CD8+ lymphocytes before and after 
treatment with dimethylfumarate 
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3) Its mean absolute count at baseline was 8 cells/μΙ, after 16 weeks a mean number of 109 
cells/μΙ was measured The absolute number of CD8+CD94+ T-cells multiplied, too (figure 4) 
Both increases were statistically significant (p= 0 02 and p= 0 04 respectively) 
Correlation with PASI-score 
A regression analysis was performed to examine if the number of T-cells in an individual 
patient shows any consistency with the PASI score However, no statistically significant linear 
correlation could be determined for any of the cell populations analysed 
Discussion 
Treatment of psoriasis with dimethylfumarate for a 16-week period has a definite effect 
on the circulating lymphocyte population in these patients Our results show an apparent 
effect on the CD4-I- populations, whereas the effect on CD8+ populations appears to be 
limited This is partly m contrast with previously reported results, in which the effect of a 
therapy with FAE seemed to be mainly directed toward the CD8-I- population13 "' Despite this 
discrepancy, the statement that fumarie acid and/or its dérivâtes have immunomodulatmg 
and immunosuppressive properties seems a truthful hypothesis Data collected in the past 
decades bring forward more and more evidence to support this theory15 
The selective effect of FAE on the CD45RO+ population and not on the CD45RA-I-
population in peripheral blood is particularly interesting Previous studies have described the 
relevance of this'memory-effector'population m the pathogenesis of psoriasis'6'7 Histologic 
studies show the presence of CD45RO+ cells m psoriatic plaques m an early phase of their 
development'8 This makes this population of T-cells very relevant m the treatment of the 
disease Frequently prescribed topical therapies have demonstrated their ability to reduce 
the number of CD45RO+T-cells in the (epi)dermis with a subsequent positive effect on the 
psoriatic skin" Recently, therapy with the biological alefacept has been introduced, which 
selectively targets the CD45RO+ cells m psoriatic plaques as well as the CD45RO+ cells in 
peripheral blood1620 The decrease in the absolute number of CD45RO+ cells shows a linear 
correlation with the clinical effect of alefacept, but also with the length of the subsequent 
remission20 So far, efficacy of alefacept is satisfactory, whereas its negative effects are limited 
Although dose-dependent reductions m circulating CD4+ and CD8+ T-lymphocytes have 
been reported, its safety profile as it is known until now is encouraging2023 Some authors 
suggest this is the merit of the selectivity of alefacept22 In this light, it is important to further 
investigate the mechanism of action of dimethylfumarate, as it shows similarities with this 
selective biological at least to some extent 
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Our results showed that dimethylfumarate reduces the CD4+CD25+ cell population 
as well. CD25 isthect-cham of the IL-2 receptor. As psoriasis is a Th-1 mediated disease, IL-2is 
one of its pro-inflammatory cytokines. As cells become activated, they start expressing CD25 
to facilitate the binding of IL-2 and promote further activation. A 16-week treatment with 
dimethylfumarate limits the expression of CD25 on CD4+ cells, and therefore seems to be of 
substantial importance when it comes to prevention of T-cell activation 
A 16-week therapy with dimethylfumarate has a significant effect on the absolute 
number of circulating CD4-I-CLA+ lymphocytes CLA is a skm-hommg receptor which is 
expressed on only a minority of peripheral T-cells24, but is present on the majority of lesionai 
T-cells. This indicates that T-cells, as soon as they mature and start expressing CLA, start 
migrating to the skin within a short period of time It has been reported that CLA+ T-cells can 
be found m lesionai skin in the early phase of plaque development25 
TheonlyCDS+subsetwhich is influenced by FAE-therapyistheCD8+CD94+population 
After 16 weeks of treatment with dimethylfumarate, a considerable increase in the absolute 
number of cells expressing both CD8 as well as CD94 was measured. CD94 is a NK-cell receptor 
which is also expressed by a subset of T-cells. Cells expressing both a Τ cell receptor (TCR) and 
a NK-cell receptor may have NK-hke properties as well as TCR-mduced properties2627 It has 
been suggested these cells have a dual function in immunity15. They might therefore play an 
important role in the pathogenesis of psoriasis The exact mechanism of action of these cells 
is still unknown, but several functions have been suggested28 31. Our findings correspond with 
the results of earlier investigations in which a reduction of NK-T-cells was found in peripheral 
blood of psoriasis patients3233 It has been suggested that downregulation of the NK-T-cell 
population results in keratinocyte hyperproliferation and immune cell activity, due to loss of 
the inhibitory effect of NK-T-cells on inflammatory processes34 
In conclusion, the effect of dimethylfumarate seems to be mainly directed toward the 
activated T-cell population In particular, CD4+, CD45RO+, CD4+CD45RO+, CD4+CD25+ and 
CD4+CLA+ cells are affected. Except for the CD8+CD94+ population, the circulating CD8+ 
cells are hardly affected. This indicates a selective, inhibitory effect of dimethylfumarate on 
the activated T-cells 
Although we studied only a small group of patients, the pattern of changes m the 
abovementioned subsets is very consistent No reductions of the absolute cell counts 
below safety levels were observed. Future studies with a larger patient selection should be 
performed to confirm its safety and to provide more evidence for its selective targeting of 
specific subsets of T-cells 
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CHAPTER 3 
Abstract 
Onercept is an agent that blocks TNF-a. Onercept has been under 
investigation for use in psoriasis. In order to study the effects of 
onercept on psoriasis-relevant circulating T-celi subsets, a substudy 
among patients participating in a phase III clinical trial with onercept 
was performed. 
The results of this study show that the number of several 
T-cell populations is increased by onercept. These increases were 
paralleled by an improvement of psoriasis from severe involvement 
(average PASI 23) to moderate-to-severe psoriasis (average 
PASI 14). it is hypothesised that these increases are the result of 
recompartmentalization of T-cells with as shift from the skin to 
peripheral blood. 
90 
EXPERIMENTAL ANTI-PSORIATIC THERAPIES 
Introduction 
Biologies comprise a group of biologic response modifiers that act at the cellular level. 
In the case of psoriasis this implies an effect on the T-cell. Based on their mode of action 
the biologies can be classified into 4 groups: T-cell reducing agents, T-cell activation and 
migration inhibitors, immune modifying agents (promoting immune deviation fromThl to 
Th2) and inflammatory cytokine blocking agents' Onercept (r-hTBP-1) belongs to the group 
of cytokine blocking agents, as do etanercept, infliximab and adahmumab2, which have 
been registered for use in rheumatoid arthritis for several years now and, more recently, for 
treatment of psoriatic arthritis and psoriasis. It is a recombinant soluble p55 tumor necrosis 
factor binding protein, that acts as a TNF-a blocker3 Onercept has been investigated in phase 
III trials for the treatment of moderate to severe psoriasis 
The aim of this study was to compare the effect of onercept on circulating T-cell 
subsets to determine its immunomodulatory effect. Previous studies have shown that the 
biologic alefacept (a LFA-3-lg fusion protein CD2 antagonist) as well as other therapeutic 
agents, such as fumarates, are capable of selectively altering the number of circulating T-cells, 
and are effective in the treatment of psoriasis for this reason"5 With regard to TNF-α blocking 
therapeutics, it is not quite clear to which extent they influence the T-cell. Surprisingly, 
intravenous infliximab is capable of rapidly increasing peripheral blood lymphocyte counts 
within 1 day of treatment6. On the other hand, studies focusing on etanercept did not show 
any effect on the amount of circulating T-cells6 7 
Phase II results have shown that 54% of the patients treated with 150 mg onercept 
three times per week achieve a reduction in Psoriasis Area and Severity Index (PASI) of 75%, 
as compared to 12% with placebo8. In order to find out to what extent this anti-TNFa therapy 
modifies peripheral T-cells, an extensive study of psoriasis-relevant T-cells was carried out 
among patients participating m a phase III clinical trial with onercept. 
Patients and methods 
Ten patients with moderate to severe psoriasis were included in the clinical trial to evaluate 
the safety and efficacy of onercept. During the first 12 weeks, all patients were treated 
subcutaneously with 150 mg of onercept three times per week. To apply for inclusion m the 
study, strict inclusion and exclusion criteria had to be met. Regular control visits were carried 
out at the outpatient clinic of the department of Dermatology. At baseline and after 12 weeks, 
peripheral blood was obtained and lymphocyte subsets were determined PASI scoring was 
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performed at each visit to monitor the clinical effect of the therapy and to find out if there is 
a correlation between clinical severity and peripheral blood parameters. 
Cell surface antigen expression was measured at baseline and after 12 weeks to 
determine the effect of onercept on circulating T-cell subsets in psoriasis on heparinized 
peripheral blood samples of 10 ml were drawn during the outpatient clinic visits. The time 
between blood withdrawal and the analyses never exceeded 24 hours. White blood cell 
counts and morphological differentiations were performed on a hematology analyzer 
(Advia, Bayer). 
Lymphocyte subsets were analyzed and counted by means of immunofluorescence 
labelled monoclonal antibodies (MoAbs) determined in multi-colour flowcytometry. The 
following MoAbs were used in combinations: CD3 (T-cells), CD19 (B cells), CD4 (T-helper cells), 
CD8 (cytotoxic cells), CD45RA (naive cells), CD45RO (memory effector cells) and CD25, CD27, 
HLA-DR (markers of activation), CD62L, CLA (homing receptors), and CD16, CD56, CD94 and 
CD161 (NK cell markers). 
Before flowcytometric analyses all erythrocytes were lysed (10 min, in the dark) 
by means of ice-cold 155 mmol/L NH4CI. (pH 7.4) according to the lyse/no wash method. 
Staining of cells was determined in 4-color analysis by using a Beekman Coulter Epics XL flow 
cytometer (Beekman Coulter, Hialeah, FL). All measurements were performed on minimally 
50,000 cells. Data (collected in list mode) were analyzed using the EXP032 ADC software 
(Beekman Coulter). 
Results 
Eight out of ten included patients completed the study: four males and four females, with 
a mean age of 46. Their Psoriasis Area and Severity Index (PASI) scores at baseline ranged 
from 9,2 to 44,2 (mean ± standard error of mean 23,1 ± 5,2). The total leukocyte count at 
baseline was 6,3 ± 0,7 x10E9 (mean ± SEM). After 12 weeks of treatment with onercept the 
mean number of white blood cells had increased to 6,8 ± 0,5x10E9. The percentages of 
lymphocytes at baseline and after 12 weeks were 24,4 ± 3,5 % and 24,5 ± 2,1 % respectively, 
which corresponds with absolute lymphocyte counts of 1,5 ± 0,2 x10E9 (mean ± SEM) and 
1,7 ±0,1 X10E9. 
The results of our study are depicted in table 1. Both percentages of each subset as 
well as absolute cell counts are summarized. 
A 12-week treatment with onercept resulted in significant changes in the absolute 
numbers of CD3+, CD3+CD4+, CD3-I-CD16.56+ and CD3+CD161+ T-cells. No differences in 
cells expressing homing receptors were found. With regard to the subcategory of activated 
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T-cells, no statistically significant changes were found, although the CD4+CD45RO+ and 
CD8+CD45RO+ populations showed a tendency to increase. 
The mean Psoriasis Area and Severity Index decreased from 23 ± 5 before treatment to 






Cell count as % of total 
(mean ± SEM) 
baseline 
66,7 ± 3,3 
18,1 ±1,6 
45,6 ± 3,5 
15,7 ±2,1 
post-treatment 
67,0 ± 3,7 
15,3 + 1,9 






256,4 ± 22,0 
670,3 ± 82,3 
246,9 ±45,6 











2,0 ± 0,5 
98,0 ± 0,5 





57,2 ± 4,2 
5,0 ± 0,9 
12,6±1,9 
1,2 ±0,3 














67,3 ± 3,7 






































8,9 ± 3,2 







298,9 ± 55,0 













8,5 ± 3,7 
4,3 ±1,3 




265,8 ± 54,3 
250,4 ±37,1 
Table I: Overview of lymphocyte subset counts in percentages and absolute numbers, at baseline 
and after the 12 week treatment period with onercept. (* p<0.05) 
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per week Individual responses varied highly, PASI reductions ranging from 28,9 to 2 One 
patient experienced an increase of disease severity during the use of onercept A correlation 
between cell numbers and PASI score could not be found 
No serious adverse events occurred during the study period The most frequently 
reported side effects of onercept were injection site reactions, such as erythema, swelling 
and pain None of the patients experienced a clinically relevant infection during onercept 
treatment 
Discussion 
The results of the present study show us that a 12 week treatment with 150 mg onercept 
subcutaneously three times per week has a significant effect on specific populations 
of circulating T-cell subsets The absolute amount of total T-cells (CD3+), T-helper cells 
(CD3+CD4+) and cells expressing NK cell markers (CD3+CD16 56+, CD3+CD161+) increased 
during treatment, whilst the skin symptoms in our study population clinically diminished 
With regard to the PASI score, a significant decrease was seen from 23 ± 5 (mean 
± SEM) at baseline to 14 ± 4 after 12 weeks (p = 0 04) Although this improvement is not 
spectacular, from a patient's point of view a PASI decrease from 23 to 14 could certainly be 
relevant with respect to quality of life It should be reconciled that the present patient group 
is relatively small, providing only a small statistical power 
Onercept treatment resulted in significant changes in some of the T-cell subsets 
investigated This finding is partly m concordance with other TNF-a blocking agents, such as 
infliximab Intravenous infliximab has the potential to rapidly increase peripheral blood cell 
count and decrease monocyte counts6 The effect of infliximab on circulating T-cells could 
possibly be explained by the fact that infliximab is a chimeric antibody and therefore has 
immunogenic effects Etanercept, however, does not have effects on circulating T-cells, but 
a decrease of the amount of lesionai CD4+ and CD8+ T-cells after a 12-week treatment (50 
mg/week) has been described9 This seems to be in contrast with the results in the present 
study An interpretation of these differences, however, remains difficult, as peripheral blood 
and lesionai skin represent two distinct body compartments 
Although the clinical trial on which this substudy is based had to be ended because 
of the adverse events of onercept, an critical effect on blood parameters is not apparent The 
observation that the absolute numbers of cells in the investigated populations remain stable 
or even increase, suggests that onercept does not cause immunosuppression by depletion of 
specific T-cell subsets 
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CHAPTER 4 
Abstract 
Background Hove\ therapies against psoriasis are emerging. Alefacept 
is such a treatment. It selectively targets the memory effector 
population of T-cells and thereby diminishes the psoriatic plaques. 
In some cases, however, the use of alefacept as a monotherapy is 
not sufficient. 
Objective In the present study we investigate the safety and 
efficacy of adding topical steroids to alefacept-treatment during the 
initial four weeks. 
Methods Peripheral blood was obtained from all patients and 
the presence of specificT-cell subsets was assessed by flow cytometry. 
Fourteen patients were included and treated with alefacept 15 mg 
intramuscular for a period of 12 weeks. Each of them was randomized 
to use either betamethasone dipropionate cream or vehicle cream 
during the first four weeks of the alefacept course. 
Results Additional topical corticosteroid treatment during 
the first four weeks of alefacept treatment does not have a beneficial 
effect on the clinical efficacy. Marked changes were seen in the 
absolute cellcounts of various of the analyzed T-cell subsets in 
peripheral blood after 12 weeks of alefacept, either with or without 
additional local steroid application. The CD45RO+- CD8CD45RO+-, 
CD8CD161+-, CD4CD25+-, CD4CLA+- and CD8CLA+-populations 
showed a statistically significant decrease immediately after the 
treatment period. Further analysis revealed that addition of local 
steroid therapy to alefacept results in marked decreases of all T-
cell subsets analyzed in this study, in contrast to addition of the 
vehiculum only. 
Conclusion Alefacept selectively targets the CD45RO+ 
lymphocyte population, as well as some other subpopulations of 
lymphocytes. This effect is independent of the use of additional 
topical therapy during the first four weeks. The extent of the decrease, 
on the contrary, is dependent on the use of corticosteroids. 
TOO 
MONOTHERAPY VERSUS COMBINATION THERAPY 
Introduction 
The continuously changing insights in the pathogenesis of psoriasis have led to changing 
therapeutical strategies'2 Recently a new generation of anti-psoriasis therapies was introduced, 
the so-called biologicals Alefacept is one of the first members of this family of recombinants 
It consists of the extra-cellular domain of LFA-3 and the Fc-portion of IgG-l and is produced in 
the Chinese Hamster Ovary by recombinant DNA technology It has been proven to selectively 
target the memory effector subpopulation of lymphocytes by inhibiting the activation of T-
cells and inducing apoptosis in critical subgroups of T-cells and NK-cells3 Studies are available 
illustrating the declining effect of alefacept on the number of circulating T-cells expressing 
CD45RO''6 Despite its immunomodulatmg mechanism of action, alefacept as a monotherapy 
seems to be relatively safe and well-tolerated79 The clinical response rate (expressed as a 
PASI reduction of at least 75%) after a 12-week treatment course was reported to be up to 
33%'° " The use of additional topical therapies to enhance the effect of alefacept treatment 
might therefore be tempting Safety aspects of combining other anti-psonatic therapies with 
alefacept are currently under investigation 
The aim of this study was to determine the safety of additional topical steroid therapy in 
combination with alefacept and to investigate possible effect-modulating capacities of these 
additional steroids For that purpose, we focused mainly on the effect of combination therapy 
on various T-cell populations in peripheral blood Furthermore, we wanted to determine if 
there is a correlation between disease severity and absolute cell counts of different circulating 
T-cell subsets m individual patients 
Materials and methods 
Patients and controls 
Fourteen patients with moderate-to-severe psoriasis vulgaris (11 male and 3 female aged 
19-66, mean age 46,2 years) from our outpatient department were included m this study 
Treatment with topical or systemic therapies was not allowed in the last two, respectively four 
weeks preceding the treatment Subjects who suffered from a clinically significant infection m 
the previous three months were excluded The mean PASI score was 21+3 (mean ± 3) 
All subjects were randomized (double-blind) to be treated either with a 12 week 
treatment course of alefacept 15 mg intramuscular in combination with 4 weeks initial 
topical treatment with betamethasone dipropionate cream once daily or with alefacept 15 
mg intramuscular in combination with 4 week initial topical treatment with the vehicle of 
the corticosteroid once daily The quantity of cream applied was limited to a maximum of 
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50 grams/week. This treatment period was succeeded by a follow-up period of 12 weeks in 
which no alefacept was administered. Peripheral blood for enumeration of lymphocytes was 
obtained immediately before the first injection (t=0), one week after the last injection (t=12 
weeks) and 12 weeks after the last study drug administration (t=24 weeks). Informed consent 
forms were signed by all patients prior to any study related measures. Approval for this study 
was obtained from the local Ethical Committee. 
Preparation ofPBMCs 
PBMC's were isolated from heparinized blood by density centrifugation on polyester gel 
(Becton Dickinson Vacutainer™ CPT™, Franklin Lakes NJ, USA). After filtering through a 70 μιτι 
cellstrainer, cells were washed twice. 
For flowcytometry, single-cell suspensions (concentration 5 · 105 cells/ ml) were stained 
in 1% Fetal Calf Serum in phosphate-buffered saline (PBS) with lymphocyte subset specific 
antibodies at concentrations recommended by the manufacturer. Additionally, 450 μΙ of 5% 
Propidium iodide (PI) in PBS was added to each sample in order to exclude non-viable cells 
from analysis. 
The following monoclonal antibodies were used: fluorescein isothiocyanate (FITQ-
conjugated anti-CD4, FITC-conjugated anti-CD8, FITC-conjugated anti-CD25, phycoerythrin 
(PE)-conjugated anti-CD4, PE-conjugated anti-CDS, PE-conjugated anti-CD94 and PE-
conjugated anti-CD161 (all from Immunotech, Marseille, France), as well as FITC-conjugated 
anti-CD45RA, FITC-conjugated anti-CLA (Becton Dickinson, San Jose CA, USA) and FITC-
conjugated anti-CD45RO (DAKO, Glostrup, Denmark). 
Flowcytometric analysis 
Cells were analyzed with a Coulter® Elite flow cytometer (Beekman Coulter Ine, Fullerton, USA). 
All samples were processed within 24 hours of phlebotomy. 
Phycoerythrin- and FITC-conjugated reagents were used, alone or in combination, to 
determine the expression of each antigen or antigen combination on lymphocytes derived 
from peripheral blood: CD4+ (T-helper cells), CD8+ (cytotoxic T-cells), CD45RA+ (naive T-
cells), CD45RO+ (memory T-cells), CD94+ (NK-cells, T-cells), CD161+ (NK-cells, T-cells with 
memory phenotype), CD25+ (activated T-cells) and CLA+ (skin-directed T-cells). Double-
labeling for CD4+ CD45RA+, CD4+ CD45RO+, CD8+ CD45RA+, CD8+ CD45RO+, CD8+ CD94+, 
CD8+CD161+, CD4+CD25+, CD4+CLA+ and CD8+CLA+ was performed. 
Determination of absolute numbers of lymphocytes 
Enumeration of positive cells was performed by adding Flow Count Beads (Beekman Coulter, 
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Fullerton CA, USA) to the cell suspension. An automatic stop after a defined amount of 
beads was programmed on the flowcytometer. Absolute counts of lymphocyte subsets were 
calculated by determining the ratio of the beads to the cell population and then multiplying 
this ratio by the number of beads in the tube. Lymphocytes were gated based on side and 
forward scatter properties; analysis was performed with Verity software. 
Ratios for CD4+/CD8+ cells, CD45RO+/CD45RA+ cells, CD4+CD45RO+/CD4+CD45RA+ 
cells and CD8+CD45RO+/CD8+CD45RA+ cells were calculated afterwards, with data derived 
from this analysis. 
Statistical analysis 
Data-entry and analysis was performed using Statistica 6.0 software. Means and standard error 
of mean (SEM) were calculated for each parameter and were tested with one-way ANOVA. 
Differences were considered statistically significant at p< 0.05. 
Results 
Fourteen patients with moderate-to-severe psoriasis were included in this study. The mean 
PASI score at study day 1 (figure 1) was 21 ± 3 (mean ± SEM). Four patients left the study 













prematurely. In all cases this was due to unacceptable worsening of the disease. No decreases 
in absolute CD4-t-T-cell counts below safety level were observed and no serious adverse events 
were reported during the course of the treatment or in the follow up period. 
Treatment period 
The mean absolute cellcounts of the various T-cell subsets for the total group of patients 
at baseline are summarized in table I. After 12 weeks of treatment, all subpopulations of 
lymphocytes had decreased, although the extent of this decrease varied widely. For the 
single-stained cells the reduction of their absolute number was for the most part a tendency. 
Significance could only be reached for the CD45RO-I- population. 
As far as the double-stained cells concerns, a statistically significant decrease in 
the absolute numbers of CD8-I-CD45RO-I-, CD8+CD161+-, CD4+CD25-I-, CD4+CLA-I- and 
CD8+CLA-I- cell populations was found (table I). All other subsets also showed a decline in the 
Cellcounts in cells/mm3± SEM 
Baseline t=12 t=24 
Total cells 4442 ± 1230 2591 ± 1043 6313 ± 961 
CD4 1567 ± 529 1071 ± 403 2308 ± 392 
CD8 1095 ± 366 508 ± 175 1086 ± 172 
CD45RO 1040 ± 280 384 ± 122(*) 1065 ± 185 
CD45RA 1200 ± 757 1050 ± 317 2670 ± 407 
CD94 766 ± 408 275 ± 218 379 ± 125 
CD161 1091 ± 486 354 ± 184 705 ± 135 
CD25 31 ± 9 11 ± 6 44 ± 11 
CLA 120 ± 3 0 42 ± 12 128 ± 24 
CD4CD45RO 691 ± 216 341 ± 90 852 ± 133 
CD4CD45RA 564 ± 340 317 ± 126 911 ± 216 
CD8CD45RO 259 ± 8 8 83 ± 31 {*) 225 ± 45 
CD8CD45RA 554 ± 282 368 ± 1 4 4 808 ± 116 
CD8CD94 233 ± 1 3 5 84 ± 65 78 ± 22 
CD8CD161 324 ± 143 76 ± 47(*) 161 ± 34 
CD4CD25 26 ± 7 10 ± 6(*) 34 ± 8 
CD4CLA 54 ± 1 6 17 ± 4(») 71 ± 18 
CD8CLA 26 ± 9 6 ± 2 C) 34 ± 13 
Table I: Absolute cellcounts of T-cell subsets for the total group of patients, regardless of the use of 
additional corticosteroid cream (mean ± SEM; *p<0.05) 
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absolute amount of cells, however, none of them could be confirmed statistically. The PASI-
score decreased from 21 ± 3 to 11 ±2 during the 12-week treatment period This reduction is 
statistically significant (p<0 05) 
Follow up period 
After the follow up period (24 weeks after the first injection with alefacept), the absolute 
cellcounts of all subsets had returned to their initial values or even exceeded these, except for 
the CD8+CD94+ population, which decreased slightly during the 12-week follow up (table I). 
None of the increases in absolute cell numbers of the various subsets, nor the further reduction 
of the CD8CD94+ population was statistically significant as compared to the values at week 12. 
During the follow up period the PASI-score showed a further, non-significant, reduction from 
11 ± 2 to 9 ± 3. 
Worsening of disease occurred m 4 out of 10 patients during follow up No correlation 
was found between this aggravation of psoriasis and the (change in) cell numbers of a specific 
lymphocyte subset m this period. 
Regarding the ratios of the CD4+ and CD8+ population and the CD45RA+ and CD45RO-I-
population and their combinations during the treatment period, we found an increase m 
the CD4+/CD8+ ratio and decreases in the ratios of CD45RO+/CD45RA+-, CD4CD45RO+/ 
CD4CD45RA+- and CD8CD45RO+/CD8CD45RA+. The CD4/CD8-ratio increased from 1,7 ± 0,4 
(mean ± SEM) at baseline to 2,2 ± 0,4 at t=12 weeks and 2,3 ± 0,3 at t=24 weeks (figure 2) No 
significant differences were found between t=0, t=12 and t=24 weeks 
The ratio of CD45RO/CD45RA decreased during the 12-week treatment from 0,7 ± 0,1 
at baseline to 0,4 ± 0,1 and 0,4 ± 0,1 after 12 and 24 weeks, respectively The CD8CD45RO-I-/ 
CD8CD45RA+ ratio decreased from 0,5 ± 0,2 at baseline to 0,3 + 0,05 at week 12 and 0,31 ± 0,06 
at week 24. The CD4CD45RO+/CD4CD45RA ratio showed a decrease from 2,4 ± 1,0 at baseline 
to 2,1 ± 0,72 at week 12 and 1,4 ± 0,3 at week 24. Unlike the results on the T-cell markers, 
which returned to their original value after cessation of alefacept therapy, the decrease of the 
calculated ratios during treatment remained relatively stable m the follow up period 
T-cell counts in relation to PASI-score and body surface area 
During the treatment phase of the study both the mean PASI score as well as the mean counts 
of the T-cells subsets decreased, or at least showed a tendency to decrease However, there 
was no significant correlation between the clinical severity of psoriasis m individual patients, 
as assessed by PASI-score, and the levels of circulating lymphocyte subsets. Nor have we been 
able to find a relation between the body surface area affected and the individual changes m 
the numbers of absolute T-cells. After treatment, during the follow up period, the PASI score 
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decreased slightly, whereas the absolute cellcounts of the aforementioned subsets recovered 
to their baseline values. 
Additional topical corticosteroid ointment during alefacept therapy 
Addition of the betamethasone-dipropionate cream during the first four weeks of treatment did 
not have a supplementary effect on the clinical efficacy of alefacept. With respect to the effect 
on cell biological parameters: a combination of the two aforementioned therapies does seem 
to have an additional effect on the decrease of the absolute lymphocyte counts, in contrast with 
its effect on clinical picture. Comparison of both groups of patients (one group with additional 
topical corticosteroid cream, one group with vehicle cream only) after the 12 week treatment 
period, showed obvious differences in the response rates (figures 3 and 4). Baseline values 
in both groups did not differ significantly, but after twelve weeks a more obvious decrease 
in absolute T-cell counts could be measured in patients using alefacept in combination with 
betamethasone dipropionate cream, as compared to the group using alefacept in combination 
with the vehicle cream only (80% vs. 46 % respectively).This decrease was statistically significant 
for the CD45RO+, CLA+ and CD8CD45RO+ populations. As mentioned before, four out often 
lt=0 at=12 Dl=24 




Figure 2: Ratios of CD4/CD8, CD45RO/CD45RA, CD4CD45RO/CD4CD45RA and CD8CD45RO/ 
CD8CD45RA, measured before and after alefacept therapy, and after the 12-week follow up period 
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patients developed new lesions during treatment or follow up period This was irrespective of 
the use of betamethasone dipropionate during the treatment period. 
Discussion 
The extent of the decreases in absolute T-cell counts showed an apparent correlation with the 
use of topical betamethasone dipropionate in combination with alefacept, as compared to the 
use of the vehiculum only. Although topical steroids are known to be potent anti-psoriatics12, 
no statistically significant difference could be found between the two study groups with 
respect to the clinical effect of additional topical treatment with steroids during the first four 
weeks of alefacept treatment. These are remarkable findings, implicating that dermatosteroids 
have little or no effect on the clinical signs and symptoms of psoriasis, but a noteworthy effect 
on systemic biomarkers, at least in the patient population selected for this study. The patients 
selected for participation in this study all had an extensive and, perhaps more important, 
therapy-resistant form of psoriasis, which could be an explanation for our findings. To apply 
for participation in this study, patients had to discontinue their regular therapies for at least 
two (topical treatment) or four (systemic treatment) weeks. Therefore, it is not unlikely that the 
patients in our study-population were suffering from an active and possibly worsening form of 
psoriasis during the first four weeks of treatment, due to the wash-out period obliged in this 
study. This could perhaps clarify the inconsistency between the effect on absolute T-cell counts 
and the clinical effect of additional topical corticosteroid application during the first four weeks 
of alefacept-treatment: steroids are potent enough to achieve an effect on circulating T-cells, 
but in case of an aggravating form of psoriasis they are not effective enough to accomplish 
a statistically significant clinical effect, at least not in this particular treatment regimen. In 
these cases, it is conceivable that migration of activated T-cells from the blood compartment 
has already taken place, and therefore the proliferation of T-cells in the psoriatic plaques can 
continue to go on. The type of application used might play a role, too. For this study a cream 
was chosen; perhaps an ointment would have had more effect on the clinical picture. Results 
of comparative studies between creams and ointments are still controversial13 '5. 
Patients were instructed to apply the betamethasone-dipropionate cream thinly, once 
a day, with a maximum of 50 grams per week. According to patient-reports, compliance in both 
groups was equal. However, considerable differences were found with regard to the amount of 
cream used per patient. These differences were related to the differences in body surface area 
affected, which varied between 10 and 70%. Despite this wide range, no correlation 
could be found between the total area affected (and thus the amount of cream applied) and 
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Figure 4: Mean absolute cellcounts in cells/mm3 for the double stained populations at baseline, after 12 weeks of treatment and after the 
§ follow up period for both patient groups. ('+ CS': with topical corticosteroid cream;'- CS': vehicle cream only) (*p<0.05) 
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The decreases in the CD4CD45RO/CD4CD45RA and CD8CD45RO/CD8CD45RA-ratios 
after therapy imply that the proportion of CD45RO+T-cells (memory-effector population) is 
decreased by alefacept. This confirms earlier evidence that alefacept selectively targets this 
population of immunocytes, which is said to play a key role in the pathogenesis of psoriasis16. 
Our results imply that the addition of topical corticosteroid treatment to a treatment with 
alefacept influences the absolute numbers of circulating T-cell subsets. This finding is of 
particular importance, as topical therapies are frequently added to systemic treatments in daily 
practice, assuming this is a safe intervention. Our study shows, that in the case of alefacept, the 
addition of a topical corticosteroid enhances its systemic effect on peripheral blood T-cells. It 
could therefore be questioned if our perception of the benign nature of combining topical 
therapies with systemic treatments is correct. It is clear, however, that although the number of 
cells of the different subsets maintained well above the defined safety levels and all returned to 
their normal values after cessation of therapy, no premature assumptions can be made about 
the safety of adding a local therapy to a treatment with alefacept. Future studies should ideally 
be performed in a larger population, with a stable form of plaque psoriasis and with the use of 
an steroid ointment in stead of a steroid cream. 
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Abstract 
Objective Alefacept is a biologic treatment for psoriasis, with a 
selective effect on memory effectorT-cells. Only few data are available 
on the combination of alefacept with either topical or systemic anti-
psoriatics. We studied the effect of alefacept combination treatment 
on clinical disease severity scores and on circulating T-cell subsets. 
Methods Twelve patients with moderate-to-severe psoriasis 
were included and treated with alefacept for a period of 12 weeks. 
Patients were allowed to continue the anti-psoriatic therapies they 
used prior to the study. Severity of disease and expression of T-cell 
markers CD4, CD8, CD45RA, CD45RO, CD94, CD161, CD25, and CLA 
were assessed at baseline and after treatment. 
Results Seven of 12 included patients used a concomitant 
systemic therapy: either methotrexate(n=4), acitretin(n=2) or 
cyclosporine(n=1). PASI reductions in this group after 12 and 24 
weeks were 40% and 55% respectively. Several lymphocyte subsets 
showed a reduction in circulating numbers. These decreases were 
independent of the use of an additional systemic psoriasis therapy. 
Conclusions The concomitant use of systemic anti-psoriatic 
medication in combination with alefacept has a noteworthy impact 
on efficacy results. No differences in circulating psoriasis-relevant 
T-cell populations between patients with or without an additional 
systemic treatment were seen. 
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Introduction 
Alefacept is a biologic treatment for psoriasis, with a selective effect on memory effector T-
cells'A. It is a fully human recombinant fusion-protein. The safety and efficacy of this biological 
as a monotherapy have been extensively studied by several investigators5 8. So far, only few 
data are available on combination therapies of alefacept with either topical or systemic 
treatments. 
Earlier investigations have shown that 33% of the patients reaches at least 75% 
improvement in baseline Psoriasis Area and Severity Index (PASI 75), and 57% of patients 
reaches at least 50% improvement in baseline PASI (PASI 50) at any time during the 12 week 
active treatment period or the subsequent 12 week follow up period9 10. At the primary 
endpoint (2 weeks after the 12 week active treatment course), 21 % of the patients had reached 
PASI 75(8). It has been suggested that the effect of alefacept could possibly be enhanced by the 
simultaneous administration of another anti-psoriatic therapy .Ina previous study, we showed 
that application of topical corticosteroids during the first four weeks of alefacept treatment 
does not have a clear additional effect on the clinical results of alefacept therapy. However, 
in the same study, the addition of a potent topical corticosteroid to alefacept does increase 
the effect alefacept has on circulating T-cell subsets in psoriasis, in particular the CD45RO+, 
CD8+CD45RO+, CD8+CD161+, CD4+CD25+, CD4+CLA-I- and CD8-I-CLA+ cells. Other authors 
have reported encouraging results of combination therapies of alefacept with UVB" '2, and 
with tapering doses of methotrexate and cyclosporine13. Faster remission of psoriasis and 
higher efficacy were noticed, whereas adverse events were not more frequently seen and T-
cell counts remained above normal levels. 
T-cells can be seen as important parameters to monitor the safety and efficacy of 
alefacept therapy. As alefacept has a direct effect on T-cells, mainly the CD45RO+ population, it 
is advised to closely monitor the absolute numbers of lymphocytes in peripheral blood during 
and after treatment14. In this context, it is recommended to check the absolute cell counts of 
CD3+, CD4+ and CD8+ cells weekly. These parameters are reliable, and representative for the 
immunologic status of the patient. So far, information on the effect of alefacept in combination 
with other treatments on a more extensive T-cell subset repertoire is not available. This study 
was designed to examine the added value of alefacept in refractory psoriasis when combined 
with other systemic anti-psoriatic therapies, as used in daily practice. Clinical scores, safety 
parameters and effects on T-cell subsets which have been suggested to play a role in the 
pathogenesis of psoriasis were investigated. 
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Materials and methods 
Patients 
At the outpatient clinic ofthe Department of Dermatology ofthe Radboud University Medical 
Centre Nijmegen, we included 12 patients for a compassionate use programme with alefacept. 
Inclusion and exclusion criteria are outlined in table I. Furthermore, we decided to treat only 
those patients who had used at least one systemic therapy or phototherapy in the past. 
Patients were permitted to continue their usual anti-psoriatic therapies in combination with 
the biological. All topical as well as systemic medications were allowed, regardless of dosing 
regimen. Injections of 15 mg alefacept intramuscular were given once weekly during 12 
consecutive weeks, with a subsequent follow up period of 12 weeks. 
Efficacy assessments 
Severity of disease was determined at baseline, after 12 weeks of treatment and at the end of 




- have a diagnosis of moderate to severe chronic plaque psoriasis 
- be candidate for systemic or photo therapy 
- be unable to use current systemic treatments due to: 
a) previous inadequate response 
b) side effects 
c) contraindications 
- have normal CD4+ Τ lymphocyte counts prior to initiation of therapy 
- sign a written informed consent in accordance with the requirements for 
compassionate treatment with unlicensed drugs 
Patients should NOT: 
- have unstable, erythrodermic or pustular psoriasis 
- have a diagnosis of guttäte psoriasis 
- have serious local or systemic infection within 3 months prior to the first 
dose of alefacept 
- be positive for HIV-antibody 
-have a history of ora new diagnosis or treatment of an invasive 
malignancy within 5 years of treatment 
- have laboratory or clinical evidence of tuberculosis 
- have current treatment for active tuberculosis or tuberculosis prophylaxis 
- be unwilling to practice effective contraception (for female patients, 
unless postmenopausal or surgically sterile) 
- be pregnant or breastfeeding (females) 
- be enrolled in any investigational drug study 
Table I: Inclusion and exclusion criteria for participation in a compassionate use program with 
alefacept 
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by PASI (Psoriasis Area and Severity Index) and PGA (Physician's Global Assessment). The PASI 
score ranges from 0 to 72, with the highest value representing very severe psoriasis. The score 
is based on 4 parameters: erythema, induration, scaling and Body Surface Area. The PGA is a 
7-point scale indicating the severity of disease as determined by the physician. It ranges from 0 
(clear, no signs of psoriasis) to 6 (severe psoriasis, very marked plaque elevation, scaling and/or 
erythema). 
Safety monitoring 
Monitoring of patients during their treatment with alefacept occurred according to the 
protocol recommended by Biogen Idee.The protocol for safety assessments is outlined in table 
II. Therapy was interrupted when considered necessary (e.g. clinically significant infection, 
absolute CD4+ lymphocyte count below 250 cells/μΙ). 
Preparation ofPBMC 
Cells were stained and processed according to the following protocol: prior to the alefacept 
injections at baseline and after 12 weeks, venapunction was performed to obtain 8 ml of 
blood. PBMC's were isolated from heparinized blood by density centrifugation on polyester 
gel (Becton Dickinson Vacutainer™ CPT™ , Franklin Lakes NJ, USA). Cells were filtered through 
a 70 urn cellstrainer and were washed twice. Single-cell suspensions were stained in 1% 
Fetal Calf Serum (FCS) in phosphate buffered saline (PBS), using the following monoclonal 
antibodies: fluorescein isothiocyanate (FITC)-conjugated anti-CD4, FITC-conjugated anti-CD8, 
FITC-conjugated anti-CD25, phycoerythrin (PE)-conjugated anti-CD4, PE-conjugated anti-CDB, 
PE-conjugated anti-CD94 and PE-conjugated anti-CD161 (all from Immunotech, Marseille, 
France), as well as FITC-conjugated anti-CD45RA, FITC-conjugated anti-CLA (Becton Dickinson, 
Physical examinations: every closing and follow up visit 
Vital signs (temperature, heart rate, blood pressure) 
Infection assessment 
Adverse events 
Laboratory Safety Assessments: monthly 
Hematology: complete blood count, differential and | 
Blood chemistry: urea, creatinine, sodium, potassium 
AST, LDH, alkaline fosfatase 
Urine pregnancy test 
Product-specific Safety Assessments: weekly 
Total lymphocyte count 
Lymphocyte subset analysis 
Dlatelet count 
, chloride, bicarbonate, total bilirubin, ALT, 
Table II: schedule for safety monitoring activities during alefacept treatment 
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San Jose CA, USA) and FITC-conjugated anti-CD45RO (DAKO, Glostrup, Danmark). Propidium 
Iodide (PI) in PBS 5% was added to exclude non-viable cells from analysis. 
Flow cytometry 
All samples were processed immediately after obtaining them. Enumeration of lymphocytes 
and T-cells was performed using a Coulter® Elite Flow Cytometer (Beekman Coulter Ine, 
Fullerton, USA). Cells were gated based on side and forward scatter properties. By adding Flow 
Count Beads (Beekman Coulter, Fullerton, USA), determination of the number of positive cells 
was facilitated. Absolute cell counts of lymphocytes expressing the following (combinations 
of) markers were determined: CD4, CD8 (cytotoxic T-cells), CD45RO (memory effector T-cells), 
CD45RA (naive T-cells), CD94, CD161, CD25 (activated T-cells), CLA (cutaneous lymphocyte 
associated antigen; skin-homing T-cells), CD4/CD45RO, CD4/CD45RA, CD8/CD45RO, CD8/ 
CD45RA, CD8/CD94, CD8/CD161, CD4/CD25, CD4/CLA and CD8/CLA. Parallel measurements 
of CD4+ and CD8+ cells were performed in the GLP certified Central Hematology Laboratory 
in our hospital, and functioned as control values. 
Analysis of results 
Analysis of the number of positive T-cells was performed with Verity WinList 5.0 software. 
Statistical analysis was carried out with the use of Statistica 6.0 software. Results were 
considered statistically significant at p<0.05 
Results 
Twelve patients were selected to be treated with alefacept 15 mg intramuscular for 12 weeks. 
Eight males and four females were included, their ages ranging from 23 to 76 years (mean 
49.6). All of them completed the entire 12-week treatment course. Concomitant medications 
used were methotrexate (n= 4), acitretin (n= 2) and cyclosporin (n= 1 ). The dosing regimens of 
these therapies did not change during the treatment period. 
Patients not currently using any systemicanti-psoriatictherapy did use topical treatments 
to control their psoriasis. They all had an extensive treatment history with regard to systemic 
anti-psoriatic therapy, and a recalcitrant form of psoriasis. The use of the local therapies varied 
from once to twice daily, and from a few days up to 12 weeks daily applications. Furthermore, 
the applications used were very diverse. Due to these disparities, the use of topical treatments 
has not been analysed. 
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adverse events 
Adverse events were monitored weekly. One of the patients had to interrupt therapy for 3 
weeks, due to an infection of the upper respiratory tract, requiring temporary discontinuation 
of alefacept therapy. The infection disappeared within a reasonable period of time, after 
intervention with antibiotics, and without sequela. Overall, no serious adverse events occurred 
during the treatment period, nor in the follow up period. Cold chills, headache and fatigue 
were the most frequent adverse events, reported by five, three and two out of 12 patients, 
respectively. All these adverse events disappeared spontaneously, without interventions, after 
the 12 week treatment period was finished. No injection site reactions occurred. 
Treatment history 
All patients participating in this compassionate use program had been treated with one or 
more systemic- or phototherapies in the past. In our study, the average number of these 
previously used therapies in was 3. UVB and methotrexate had been by far the most frequently 
prescribed treatments, with 10 respectively 9 patients having used it. Fumarates had only been 
used by 2 out of 12 patients. 
T-cell subsets 
CD4+ and CD8+ cellcounts were performed weekly by means of automated flowcytometry 
in the GLP certified Hematologic Laboratory in the Radboud University Nijmegen Medical 
Centre. Lymphocyte phenotyping for other relevant subsets of T-cells was done at baseline 
and after 12 weeks of treatment. These measurements were performed in the Dermatology 
Research Laboratory in the aforementioned institution. We were able to obtain a complete set 
of samples from 8 out of 12 patients. 
As depicted in figure 1, the average absolute numbers of the total group of CD3+, CD4+ 
and CD8+ lymphocytes all showed a slight tendency to decrease. No statistical significance 
could be achieved for any of these subsets. When comparing the group of patients using an 
additional systemic therapies with the group of patients who did not, no differences in the 
extent of the decreases could be found. None of the patients had to interrupt therapy because 
of low CD4+ T-cell counts. However, there was one subject whose CD4+ dropped below 
the safety level of 250 cells/μΙ right after the last alefacept injection. We retested again after 
one week and CD4+ counts proved to be normal again. 
The mean CD4/CD8 ratio before initiation of alefacept therapy was 1,9. During therapy, 
this ratio increased to 2,1 after alefacept treatment, and to 2,5 after the complete follow up 
period of 12 weeks. None of these increases reached statistical significance. 
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Statistically significant differences could be found in the absolute numbers of CD45RO+ 
(p<0.01), CD45RA+ (p<0.05), CD161+ (p<0.05), CD4+CD45RO+ (p<0.01), CD4+CD45RA+ 
(p<0.05), CD8+CD45RO+(p<0.05), CD4+CD25+ (p<0.05), CD4+CLA+ (p<0.01) and CD8+CLA+ 
(p<0.05) T-cells after 12 weeks of treatment with alefacept. Lymphocytes expressing these 
(combinations of) cellmarkers were all decreased, as compared to prior to initiation of therapy. 
These decreases were independent of the use of an additional systemic anti-psoriatic therapy 
in combination with alefacept. The absolute numbers of the various subsets of T-cells before 
and after the 12-week treatment course with alefacept and after the 12-week follow up period 
have been summarized in figures II and III. In figure IV, the same data are presented, with 
a subdivision made between patients on concomitant topical and on concomitant systemic 
therapy. 
Safety 
Combination therapy of alefacept with the systemic therapies used in this study seems to be 
safe. No unusual side effects, such as opportunistic infections occurred during or after the 
treatment period. The occuring adverse events all disappeared after cessation of alefacept 
therapy. As far as topical therapy concerns: ointments and creams were only applied when 
needed in the patients opinion. Therefore, no further statistical evaluations were made. 
Absolute cellcounts 
-•-CD3 -»-CDA 
Figure 1 : Cellcounts of CD3+, CD4+ and CD8+ cells during and after treatment with alefacept 
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Figure 2: Absolute cell counts (cells/mm3) before and after 12 weeks of therapy with 15 mg alefacept 
intramuscular; single stained cells 
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Laboratory parameters for clinical chemistry and haematology were measured before 
initiation of alefacept therapy, and monthly during the treatment period. Only one patient 
experienced an increase in the levels of ALT and AST, slightly above the upper levels of normal. 
No other significant changes in laboratory measurements occurred. 
Efficacy 
The mean RASI reduction for the total group of 12 patients was 37% (p< 0.001) after 12 
weeks of (combination) treatment with alefacept, whereas the PASI-reduction after the follow 
CD4CD45RA CD4CD45RO CD8CD45RA 
0 12 24 0 12 24 0 12 24 
CD8CD45RO CD8CD94 CD8CD161 
Bl | 
0 12 24 
0 12 24 0 12 24 
CD4CD25 CD4CLA CD8CLA 
0 12 24 0 12 24 0 12 24 
Figure 3: Cell counts (in cells/mm3) before and after 12 weeks of therapy with alefacept; double-
stained cells 
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up period did not exceed 33% (p< 0.01). The loss of PASI-reduction between week 12 and 
week 24 is non-significant. Subdividing the patients into two categories, one with and one 
without concomitant systemic therapy, showed the following results: for the patients using a 
combination therapy, the PASI-reductions after 12 respectively 24 weeks were 40% {p< 0.001) 
and 55% (p< 0.01); for the group not using any additional systemic anti-psoriatic therapy these 
percentages were 32% (p< 0.05) and 9 % (non-significant), respectively. 
When observing individual results, these are the outcomes: after 12 weeks of treatment, 
4 out of 12 patients participating in this compassionate use program had reached a PASI 50. 
Two of these patients were using a concomitant systemic treatment (both MTX), the other two 
were using only local therapies or nothing at all. As far as the PASI 75 concerns, none of the 
patients reached this value after the 12 week treatment period. After 12 weeks of alefacept 
therapy, all patients discontinued alefacept and continued their anti-psoriatic therapy during 
the subsequent follow up period. At the end of this period, 4 patients had achieved a PASI 
50. Interestingly enough, only two of them belonged to the subjects experiencing a PASI 50 
duringactivetreatment with alefacept.Two out of 12 patients reached a PASI 75 at the end of 
the follow up period. Both of them belonged to the group of patients with PASI 50 at 12 weeks, 
and only one of them was using an additional anti-psoriatic treatment. The average PASI score 
of the entire group decreased from 17.7 at baseline to 11.0 at week 12 (p< 0.01) and to 10.6 
after the follow up period (p< 0.01). Table III shows an overview of the PASI scores at baseline, 
after 12 weeks and after the follow-up period. 
Physician Global Assessment (PGA) scores were obtained on a regular basis during the 
treatment period and after follow up. The PGA after 12 weeks as compared to the baseline 
PGA had improved in 7 out of 12 patients, remained stable in three patients and deteriorated 
in two patients. After the follow up period, the number of patients who achieved a PGA of 
"clear" or "almost clear" was two, whereas in seven patients the PGA score did not differ from 
their baseline PGA or worsened. The worsening of the PGA scores was independent of the use 
of concomitant systemic therapy. Three out of 7 patients were using additional anti-psoriatic 
therapy. 
Total group (n=l 2) 
Concomitant systemic treatment (n=7) 
Concomitant topical treatment (n=5) 
















The present report describes the clinical response of 12 patients with severe psoriasis to a 12-
week treatment course with alefacept, whilst continuing the topical and/or systemic treatments 
which these patients received already. As in daily praxis, in contrast to the clinical trial situation, 
combination treatment is the reality in the vast majority of patients. The "added value" and the 
"added safety" of a treatment such as alefacept is therefore relevant. In this report we describe 
the outcomes after 12 weeks of active treatment and after 12 weeks of follow up. The latter 
is relevant, as alefacept has been suggested to have a remittive efficacy, reaching optimal 
improvement well after discontinuation of active treatment15. As this present study comprises 
a variety of treatments, it should be regarded as an exploratory pilot study. 
In the present study, an alefacept course added to both topical (n=5) and continuous 
systemic treatment (n=7) did not have clinically relevant side effects. In a previous multicenter 
study on combination treatment with alefacept, methotrexate and cyclosporin were 
discontinued during the alefacept course; safety parameters in this study remained essentially 
normal16. In another study performed in our clinic, the combination of alefacept with 
betamethasone dipropionate proved to have no clinical side effects although the following 
T-cell subsets decreased beyond the decrease induced by alefacept monotherapy: CD45RO+, 
CD8+CD45RO+, CD8+CD161+, CD4+CD25+, CD4+CLA+ and CD8+CLA+ (article submitted). 
The CD3+, CD4+ and CD8+ cell counts in the present study were assessed weekly during active 
treatment and monthly during follow up (figure 1). A slight reduction of all cells numbers 
occurred during the active treatment period. During follow up the cell counts did not further 
reduce, nor did they return to their baseline values. 
The other T-cell subsets, as shown in figure 2, were reduced significantly after 12 weeks 
active treatment. The decreases observed in these parameters were comparable to reduction 
as reached during other systemic treatments for psoriasis. During fumarate treatment for 
example, CD4+, CD45RO+, CD4+CD45RO+, CD4+CD25+ and CD4+CLA+ cells reduced with 
more than 50% of baseline values, which is close to the reductions observed in the present 
study. Those patients who were on treatment with topical applications only (n=5), had similar 
reductions of T-cell subsets during alefacept as patients using a concomitant classical systemic 
therapy (n=7). After the follow up period, the absolute cell numbers of almost all of the subsets 
had increased again, sometimes even slightly exceeding baseline levels.Therefore, the present 
cases illustrate that the classical systemic treatments can be combined safely with alefacept. 
Furthermore, it is feasible that the reductions in absolute T-cell numbers are not treatment 
specific and therefore may be the result of the improvement of psoriasis. 
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After the 12 week treatment course with alefacept, the overall mean PASI score had 
decreased with 37%. This percentage is only slightly higher than previously published data 
on the efficacy of alefacept monotherapy, in which an efficacy rate of 33% was reported. If we, 
however, separate the patients also using classical systemic therapies from the ones on topical 
treatment only, the differences become more marked. The efficacy increases to 40% for the 
former, and decreases to 32% for the latter. After 24 weeks (12 weeks of treatment and a follow 
up period of 12 weeks) the PASI reduction for patients using classical systemic treatments has 
increased to 55%, whereas the mean PASI reduction in the other group declined to 9%. 
It seems that the concomitant use of systemic anti-psoriatic medication in combination 
with alefacept has a noteworthy impact on the efficacy achieved during the first 12 weeks of 
treatment, but it even has a more powerful effect on the long-term results after a 12 week 
follow up period. Use of an additional systemic anti-psoriatic therapy prolonges and improves 
the effect of alefacept considerably, while its effect on the PASI score dissolves more rapidly in 
those patients who used topical therapy only in addition to alefacept. It has to be taken into 
account that the patients treated with alefacept described here, belong to a category which 
are difficult to treat due to their recalcitrant psoriasis. In this context, improvement of the skin 
with 40% and 55% after 12 and 24 weeks respectively, beyond the effect of classical systemic 
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CHAPTER 5 
5.1 Introduction to discussion 
The central issue in this thesis was to study specific T-cell populations in psoriasis in order 
to extend our knowledge about their role in the disease process, and to find out if and how 
these populations are influenced by the next-generation anti-psoriatic treatments, recently 
available. We hypothesized that these treatments, which are effective in skin manifestations 
of psoriasis and psoriatic arthritis, affect systemic functions. We have chosen to make analyses 
in peripheral blood of T-cell populations and subpopulations known to be present in lesionai 
skin of psoriatic patients. These populations are: CD4+, CD8-1-, CD45RO+, CD45RA+, CD94+, 
CD161 +, CD25+ and CLA+ T-cells. In section 1.5, the major aims of the thesis were formulated. 
By answering the selected questions (section 1.5) we tried to gain insight in: 
I. The contribution of T-cells subsets to the pathogenesis of psoriasis 
II. The role of circulating T-cell subsets as a target for anti-psoriatic treatments 
III. Safety issues related to reductions of T-cell subsets during antipsoriatic treatment 
In the following sections, the findings in chapters 2,3 and 4 will be discussed and summarised 
in order to understand better the role of T-cells in the pathogenesis of psoriasis, the role of T-
cells as an antipsoriatic target and safety of T-cell targeted treatments assessed by monitoring 
T-cell subsets during these treatments. 
5.2 The contribution of T-cell subsets to the pathogenesis of psoriasis 
The first aim of this thesis was to characterize T-cells in the peripheral blood of untreated 
psoriatic patients. Whereas the presence of T-cells in lesionai, but also uninvolved psoriatic 
skin has been extensively investigated14, data on psoriasis relevant T-cells in the systemic 
compartment are relatively sparse, and still controversial (chapter 2). Understanding the 
pathogenesis of psoriasis with respect to T-cell subsets also has major practical implications 
as new antipsoriatic treatments have become available focussed on T-cell targets. In order to 
understand the changes of the numbers of T-cell subpopulations during systemic treatments, it 
is important to have univocal information on T-cell subsets in peripheral blood before therapy 
and in particular it is important to know the relationship between the number of T-cell subsets 
and disease severity. It is in the light of further understanding of the pathogenesis of psoriasis 
that the first two studies described in chapter 2 have been performed. 
In these studies, we have shown that the number and distribution of circulating T-cell 
subsets in psoriasis do not differ from healthy subjects, as long as disease severity is mild (PASI 
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<12) However, with climbing PASI scores, apparent changes in the number of T-cells subsets 
in the systemic compartment are seen Nearly all investigated T-cell subsets increase when 
PASI score climbs to a moderate-severe psoriasis (12 <PASI <20) However, when the severity 
of psoriasis exceeds a certain degree of severity (PASI>20), numbers of Τ cell subsets drop to 
baseline values or even below This could well be explained by an influx of T-cells into the 
skin m mild psoriasis, the cutaneous inflammatory process is only limited and the number 
of T-cell subsets in peripheral blood does not show marked changes at this point When PASI 
increases and the inflammation is becoming more substantial, T-cells in peripheral blood are 
activated and start to proliferate in the systemic compartment In the more extentive disease 
involvement (PASI >20), T-cells are recruited and migrate from the peripheral blood into the 
lesionai skin, leading to a reduction in all of the investigated circulating T-cell subset counts 
We concluded that the sizes of lymphocyte subpopulations in peripheral blood of psoriatic 
patients depend on disease severity (chapter 2) Therefore, in order to understand the effect of 
anti-psonatic treatments on these lymphocyte populations, the baseline clinical severity score 
has to be reconciled A change from severe to moderate disease or from moderate to mild 
disease severity causes in itself changes in T-cell subpopulations of peripheral blood (chapter 
2) These severity associated T-cell changes do not follow a linear relationship with disease 
severity 
The non-linear relationship between number of Τ cell subsets in peripheral blood 
and disease severity is especially relevant m the light of the recently marketed biologicals, 
which all influence T-cell subsets, either direct or indirectly512 The current guidelines of 
these medications state they should only be used in those patients, suffering from psoriasis 
with a PASI of at least 10 and who have tried virtually all established treatments for psoriasis 
without success Considering our study data, numbers of T-cells in peripheral blood are at 
their maximum when PASI score indicates a moderate-to-severe disease severity (PASI 12-
20), which suggests this severity may provide the best window to start biological therapy It 
provides experimental evidence for the hypothesis that, m very severe psoriasis (PASI >20), 
T-cells have already migrated to the site of inflammation, and therefore are not an ideal target 
anymore for systemic immunomodulatmg therapies It is remotely possible that patients 
with very severe involvement (PASI >20) may be less responsive to biological treatments as 
compared to patients with moderate to severe extent We have observed at our department 
that patients with erythrodermic psoriasis show only a modest response or no improvement 
at all to biological treatments'3,4 
Future studies, measuring both peripheral blood and lesionai T-cell subsets may 
further elucidate the mechanisms behind Τ cell compartmentalization in psoriasis Studies on 
the pathogenesis of psoriasis should involve both lesionai and peripheral blood leukocytes 
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With respect to peripheral blood leukocytes, their relevance to the pathogenesis of psoriasis 
is complicated by selective influx of psoriasis relevant T-cells into the skin, psoriasis relevant 
aspects of T-cells are more likely to be found in skin and not m peripheral blood15 '8 
5.3 T-cells as targets for anti-psoriatic treatments 
By evaluating the effect of various anti-psoriatic therapies on circulating T-lymphocytes, we 
tried to find a correlation between changes of disease severity and changes of number of T-
cells during treatment For this thesis, we focused on the evaluation of the effect of systemic 
immunomodulatory therapies with different mechanisms of action on circulatmgT-cell subsets 
alefacept, dimethyl-fumarate in its new formulation (FAG-201) and onercept Each treatment 
was investigated as monotherapy, with an exception for alefacept, whose immunomodulatory 
capacities m combination with a potent topical corticosteroid and some classical systemic 
treatments were evaluated as well We were able to reconfirm earlier findings on the reduction 
of CD4+, CD8+ and CD45RO cells during alefacept treatment19 20 In the present studies we 
have investigated the effects of the abovementioned treatments on a broad panel of psoriasis-
relevant T-cells subsets A consistent finding for both dimethyl fumarate and alefacept, but 
not for onercept, were the significant decreases in the number of circulating CD45RO-I-, 
CD4+CD45RO+, CD4+CD25+ and CD4+CLA+ T-cells after therapy However, it should be noted 
that patients treated with alefacept and fumarates had moderate to severe psoriasis, whereas 
patients treated with onercept suffered from very extensive disease As shown m chapter 2, 
the absolute cell numbers of virtually all investigated circulating T-cell subsets are decreased m 
severe psoriasis Therefore, it is hypothesized that the increases found in the CD3+, CD3+CD4+, 
CD3+CD16 56+ and CD3+CD161 + populations during onercept treatment are the resultant of 
the parallel decrease m PASI score from severe to moderate-to-severe psoriasis 
A summary of our findings for the treatments studied is given in table I 
The consistent effect of dimethyl-fumarate and alefacept on CD45RO+ and 
CD4CD45RO+ cells suggests that memory effector cells are a major target for anti psoriatic 
therapies The other cellpopulations that are significantly influenced by both alefacept and 
dimethyl-fumarate, CD4+CD25+ and CD4+CLA+ cells, revealed that these cells are activated 
and belong to the fraction of T-cells which actually are predisposed to enter the skin Therefore, 
activated, skin homing, memory effector cells are a major target for anti psoriatic treatments 
The fact that during onercept treatment the absolute cell numbers of CD3+, CD3+CD4+, 
CD3+CD16 56+ and CD3+CD161 + T-cells showed an increase, is compatible with the theory 
that the very extensive involvement of psoriasis m this study may have resulted in a depletion 
of circulating T-cell subsets Such a depletion may limit the efficacy of T-cell directed therapies 
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in very widespread disease. As the amount of circulating T-cells in the peripheral blood of 
a psoriatic patient during treatment is actually the resultant of two processes, a change of 
peripheral blood T-cells cannot be regarded as a result of the treatment without reconciling a 
change in extent of the disease. In chapter 2, evidence has been provided that the number of 
T-cells of a specific subset may increase when the PASI is declining from a severe score to a 
moderate score. In the case of the onercept study, in which the PASI declined from average 34 
at baseline to 21 after 12 weeks of therapy, the expected increase in T-cells has actually been 
observed in some subsets. 
The changes of the number of T-cells in peripheral blood by an antipsoriatic treatment 
therefore is the resultant of (i) the change in T-cell numbers due to the improvement of disease 




































































































Table I: Changes in the expression of T-cell markers after therapy with dimethylfumarate, alefacept 
in combination with class III topical corticosteroids, alefacept in combination with systemic therapy 
and onercept, respectively.The arrows indicate decreases and increases in the absolute cell numbers 
as compared to baseline. 
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In the future, parallel studies of T-cell subsets in peripheral blood as well as in skin should be 
performed to substantiate this hypothesis. 
5.4 Safety issues related to reductions of T-cell subsets during 
antipsoriatic treatments 
Opportunistic infections have been reported in patients with rheumatoid arthritis, treated 
with anti-TNF-α treatments21 ". Furthermore, there is some concern that immunosuppressive 
treatments may induce malignancies. Indeed such has been reported for psoriatic patients 
treated with cyclosporine2426. As T-cell targeted systemic antipsoriatic treatments have the 
potential to reduce the number of T-cell subsets in peripheral blood (chapters 3 and 4), the 
question arises whether such treatments actually reduce immunosurveillance in psoriatic 
patients to the extent that opportunic infections and malignancies are induced. 
Infections and malignancies during treatment with alefacept, anti-TNF-a and fumarates 
Large populations of psoriatic patients have been treated in placebo-controlled clinical trials 
with alefacept and the anti-TNF-α treatments, etanercept and infliximab. During alefacept 
treatment the incidence of serious infections requiring hospitalization was 0.9%, but did 
not differ from serious infections in placebo groups. Furthermore, combination treatment of 
alefacept with various topical-and systemic anti-psoriatic treatments did not result in increased 
frequencies of infections27. In psoriatic patients treated with etanercept upper respiratory 
track infections were reported to occur in 15.2% of patients. In another study on etanercept 
infections adverse advents occurred in 13% of patients vs 11% in placebo treated patients, 
which difference was not statistically significant28. In these studies there is no indication that 
malignancies are more frequent in alefacept or etanercept treated patients as compared 
to placebo treated patients. However, alefacept and etanercept have been administered 
during a restricted period of time (3-6 months in general). Therefore we cannot rule out with 
certainty that prolonged treatment during many years might result in increased frequencies 
of (opportunistic) infections and malignancies. For this reason long-term follow up, using 
registries for patients who have been treated with biologies, is needed. 
With respect to fumarates, few placebo-controlled studies are available. However, 
in particular in German speaking countries many psoriatic patients have been treated with 
fumarates (during decades)29. No cases of serious infections have been reported in patients 
treated with fumarates and no indication for increased frequencies of malignancies have been 
reported. 
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In the studies described in chapter 4, alefacept monotherapy and alefacept in 
combination with topical corticosteroids and classical systemic treatments did not result in 
significant infections or malignancies, with the exception of one patient, using concomitant 
methotrexate for 3 weeks, who developed a respiratory tract infection. The anti TNF-a 
treatment onercept was well tolerated by the patients treated in the Nijmegen centre (chapter 
3) In particular no serious adverse events and no clinically relevant infections were reported 
However, in other centres participating m this double blind study onercept has resulted in 
several serious infections, including sepsis For this reason further development of onercept 
was discontinued. 
The relationship between reduction of T-cell subpopulations and opportunistic infections and 
malignancies 
The occurrence of opportunistic infections and malignancies in patients who had been treated 
with biologicals was not related to the absolute numbers of circulating T-cells CD4 CD8 and 
CD45R020. However, it is well possible that these patients may have had reductions of T-cell 
populations well below normal values m the past, during treatment with a biological or another 
immunosuppressive anti-psonatic drug. It is also possible that these patients may have had 
slight reductions ofT-cell population without reaching pathological levels In previous literature 
no information on reduction of T-cell subsets (memory effector cells, activated T-cells, CLA + 
cells) in relation to opportunistic infections and malignancies was available. 
In our studies, CD4+ and CD8-I- cells remained within the normal range during treatment 
with alefacept, fumarates and onercept In one patient, however, a slight and transient 
reduction below the lower level of the normal range was observed. Alefacept monotherapy 
and alefacept combination treatments, as well as fumarates caused significant reductions of 
vanousT-cell subsets (Table I), including memory effector cells, activated T-cells and CLA+ cells 
The reductions of these subsets by alefacept may suggest that these patients are at risk for 
infections or malignancies. However similar reductions have been reported during treatment 
with fumarates. Fumarates are a time honoured therapeutical principle and not the slightest 
evidence is available for increased risk for infections and malignancies during decades of 
fumarate treatment30. 
It can be concluded that no evidence is available that reductions of T-cell subsets as 
induced by alefacept and fumarates are associated with an increased risk for opportunistic 
infections and malignancies However, it cannot be ruled out by our studies that interference 
with immune function may have an impact on immunosurveillance.Therefore, patients treated 




5.5 Concluding remarks 
Patients with mild psoriasis have essentially normal T-cell subsets in peripheral blood 
Patients with moderate psoriasis have increased numbers of CD4+, CD45RO+, 
CD4+CD25+ and CD4+CLA+ subsets in peripheral blood 
Patients with severe expressions of psoriasis have populations of T-cell subsets which 
approach those observed in healthy subjects and patients with mild psoriasis 
CD45RO+, CD4+CD45RO+, CD4+CD25+ and CD4+CLA+ cells were consistently 
decreased by alefacept and dimethyl fumarate, indicating that memory effectorT-cells, 
activated T-cells and skin homing T-cells are a major target for anti-psoriatic therapies 
It was hypothesised that the increase of the absolute numbers of specific T-cell subsets, 
in parallel with the decrease of PASI from severe to moderate-to-severe psoriasis, during 
treatment with onercept, is due to the T-cell depletion in peripheral blood associated 
with the extensive involvement of patients enrolled in this study 
During treatment with the T-cell focused treatments studied in this thesis, the major T-
cell populations CD4 and CD8 were never decreased below safety level, which provides 
some reassurance with respect to the question of safety of these agents 
Decreases of CD45RO+, CD4+CD45RO+, CD4+CD25+ and CD4+CLA+ cells as induced 
by alefacept and dimethyl fumarate are unlikely to induce increased frequencies of 
opportunistic infections and malignancies. 
5.6 Suggestions for future investigations 
In this thesis, we focused on the number of psoriasis-relevant circulating T-cells only. 
As functioning of T-cells is not assessed in studies measuring numbers of these cells, it 
is possible that functional studies will provide new insights in the actual relevance of 
T-cells in the pathogenesis and treatment of psoriasis. 
The dynamics of T-cell trafficking between systemic locations and skin remains 
unknown. Migration studies in which specific T-cells are labeled and followed in their 
trafficking through the body are worthwhile, and are needed in order to gain more 
insight in the role of T-cell subsets in psoriasis. 
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CHAPTER 6 
6.1 Introductie 
Het centrale thema in dit proefschrift is de studie naar specifieke subsets van circulerende T-
cellen relevant voor psoriasis, met als doel onze kennis over hun rol in de Pathogenese van 
psoriasis te vergroten, en de invloed van enkele recent geïntroduceerde antipsoriatische 
therapieën op deze populaties vast te stellen. We veronderstelden dat de bedoelde innovatieve 
behandelingen, die effectief zijn in psoriasis en artritis psoriatica, systemische parameters 
beïnvloeden en dat hun effect niet beperkt blijft tot slechts lokaal meetbare veranderingen. 
Door in het perifere bloed van patiënten analyses te maken van diverse T-cel populaties en 
subpopulaties waarvan bekend is dat zij eveneens in aangedane huid voorkomen, hebben we 
getracht hier bewijsvoering voor te vinden. De focus lag hierbij op de CD4+, CD8+, CD45RO+, 
CD45RA+, CD94+, CD161+, CD25+ and CLA+T-cellen en verdere onderverdelingen hierin. 
In sectie 1.5 worden de belangrijkste doelen van dit proefschrift geformuleerd. We 
hebben gedurende het onderzoek getracht inzicht te krijgen in: 
I. De rol van specifieke T-cellen in de Pathogenese van psoriasis 
II. De rol van circulerende T-cellen als doelwit voor behandelingen gericht tegen 
psoriasis 
III. Veiligheidsoverwegingen met betrekking tot de verlaging van de aantallen T-cellen 
tijdens deze behandelingen 
De bevindingen zoals deze gedaan zijn in de hoofdstukken 2,3 en 4 van dit proefschrift zullen 
in het hiernavolgende gedeelte kort uiteengezet worden. 
6.2 De rol van T-cellen in de Pathogenese van psoriasis 
De aanwezigheid en fenotypering van T-cellen in zowel lesionale als niet-lesionale huid van 
psoriasispatienten is reeds uitvoerig beschreven in de literatuur. De gegevens over psoriasis-
relevante T-cellen in het systemische compartiment zijn daarentegen nog relatief schaars, 
en bovendien niet eenduidig. In hoofdstuk 2 wordt een tweetal studies beschreven waarin 
de relatie tussen ziekte-ernst en T-cellen in bloed in onbehandelde psoriasispatienten werd 
vastgesteld. Deze studies vormden het uitgangspunt voor de rest van dit proefschrift, waarin 
de invloed van diverse (combinaties van) systemische therapieën op de absolute aantallen van 
specifieke circulerende T-cel subsets werd onderzocht. 
Ze laten zien dat het aantal en de verdeling van de onderzochte subsets van T-cellen 
in psoriasis niet verschilt van gezonde proefpersonen, zolang er sprake is van een milde 
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psoriasis Wanneer de ziekte-ernst toeneemt naar PASI-scores boven de 12, zijn echter wel 
duidelijke veranderingen in celaantallen waarneembaar Vrijwel alle onderzochte circulerende 
subpopulaties laten een stijging zien tot een PASI-score van 20 (matig-ernstige psoriasis), 
doch in patiënten met ernstige psoriasis (PASI>20) dalen de celaantallen weer tot waardes 
vergelijkbaar met die van milde psoriasis en gezonde proefpersonen Dit zou verklaard kunnen 
worden door een uitwisseling van T-cellen tussen het cutané en systemische compartiment 
m milde psoriasis is sprake van slechts beperkte infiammane, welke zich met uit in meetbare 
veranderingen in T-cel aantallen m het perifere bloed BIJ matig-ernstige psoriasis is sprake 
van een meer substantieel mflammatoir proces, wat leidt tot T-cel activatie en proliferatie 
in het systemische compartiment Wanneer de ziekte-ernst nog verder toeneemt zullen de 
circulerende T-cellen gerekruteerd worden en migreren naar de huid, wat zich vervolgens uit 
m een daling van de celaantallen m het perifere bloed De grootte van de diverse populaties 
is derhalve afhankelijk van de ziekte-ernst, maar volgt geen lineaire stijging Deze bevinding 
is in het bijzonder relevant met het oog op de recent geïntroduceerde biologicals die, direct 
danwei indirect, allen een invloed hebben op T-cellen De huidige richtlijn adviseert het 
gebruik ervan alleen dan wanneer de PASI-score hoger is dan 10 en m patiënten die vrijwel 
alle andere antipsonatische therapieën gebruikt hebben Onze data laten zien dat de T-cellen 
hun maximale aantal bereiken wanneer sprake is van een matig-ernstige psoriasis (PASI 12-
20) Hieruit volgt de hypothese dat m zeer ernstige psoriasis de T-cellen reeds gemigreerd zijn 
naar de plek van mflammatie, en dat zij geen aangrijpingspunt meer vormen voor systemische 
immuunmodulerende therapieën Idealiter zou therapie met biologicals derhalve bij matig-
ernstige psoriasis opgestart moeten worden Het is denkbaar dat patiënten met een ernstige 
psoriasis (PASI>20), bijgevolg een lagere therapierespons vertonen op de behandeling met 
biologicals Deze hypothese wordt ondersteund door de bevindingen bij een tweetal patiënten 
met een erythroderme psoriasis die met of slechts matig reageerden op therapie 
Toekomstige studies zullen zich gelijktijdig moeten richten op zowelT-cellen m het bloed 
als m de huid om het mechanisme van deT-cel compartimentalisatie verder te verhelderen Het 
bepalen van de relevantie van leukocyten in het perifere bloed bij psoriasis wordt bemoeilijkt 
door de selectieve influx van psonasis-relevante T-cellen m de huid, het is waarschijnlijk dat 




6.3 De rol van circulerende T-cellen als doelwit voor behandelingen 
gericht tegen psoriasis 
Door het effect van verschillende anti-psonatische therapieën op circulerende T-cellen te 
evalueren, hebben we getracht een correlatie te vinden tussen veranderingen in ziekte-ernst 
en veranderingen m aantallen T-cellen tijdens behandeling. Voor dit proefschrift hebben we 
ons gefocust op de evaluatie van het effect van systemische immuunmodulerende therapieën 
met verschillende aangrijpingspunten op T-cellen. alefacept, dimethylfumaraat m een nieuwe 
samenstelling (FAG-201) en onercept Elke genoemde behandeling werd onderzocht als 
monotherapie, met uitzondering van alefacept, waarvan, m een tweetal studies, de immuun-
modulerende eigenschappen ook in combinatie met een krachtig lokaal corticosteroid en di 
verse conventionele systemische therapieën werd geëvalueerd (hoofdstuk 4). In deze studies 
werden eerder beschreven dalingen m aantallen CD4+, CD8+ en CD45RO+ cellen tijdens ale-
facept behandeling nog eens bevestigd de effecten van bovengenoemde behandelingen op 
een breed panel vanT-cel subsets relevant voor psoriasis werden onderzocht Een consistente 
bevinding was de statistisch significante daling van circulerende CD45RO+, CD4+CD45RO+, 
CD4+CD25+ en CD4+CLA+ T-cellen na de behandeling met dimethylfumaraat en alefacept. 
Een behandeling met onercept had op deze subsets geen invloed Hierbij dient opgemerkt 
te worden dat de bij de patiënten behandeld met dimethylfumaraat en alefacept sprake was 
van een matig-ernstige psoriasis, bij de patiënten behandeld met onercept van een ernstige 
psoriasis. In hoofdstuk 2 laten we zien dat de absolute celaantallen van vrijwel alle circulerende 
T-cel subsets afgenomen zijn bij ernstige psoriasis; het is derhalve denkbaar dat de stijgingen 
m de CD3+, CD3+CD4+, CD3+CD16 56+ en CD3+CD161+ populaties zoals deze gevonden 
werden tijdens de behandeling met onercept, het gevolg zijn van een parallelle afname van 
de PASI score van ernstige naar matig-ernstige psoriasis 
Tabel I toont een overzicht van onze bevindingen voor de afzonderlijke 
behandelingen. 
Het consequente effect van dimethylfumaraat en alefacept op CD45RO+ en 
CD4+CD45RO+ cellen suggereert dat memory effector cellen een belangrijk doelwit zijn 
voor anti-psonatische therapieën De andere celpopulaties die significant werden beïnv-
loed door beide behandelingen, CD4+CD25+ en CD4+CLA+ cellen, indiceren dat het geac-
tiveerde cellen betreft en dat deze een predispositie voor de huid hebben. Geactiveerde, 'skin 
homing', memory effector cellen lijken dus een belangrijk doelwit voor therapieën gericht 
tegen psoriasis 
De bevinding dat de absolute celaantallen van CD3+, CD3+CD4+, CD3+CD16 56+ en 
CD3+CD161 + tijdens behandeling met onercept toenemen, is in lijn met de theorie dat de zeer 
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uitgebreid aangedane huid in deze studie (hoofdstuk 3) heeft geleid tot een aanvankelijke de-
pletie van de circulerende T-cel subsets. Deze zou de effectiviteit van T-cel gerichte therapieën 
in zeer uitgbreide psoriasis kunnen beperken. Aangezien de hoeveelheid circulerendeT-cellen 
in het perifere bloed een resultante is van twee processen, kan een verandering in het aantal 
hiervan niet alleen gezien worden als het resultaat van de behandeling, zonder hierbij ook de 
verandering in ziekte-ernst in acht te nemen. In hoofdstuk 2 laten we zien dat het aantal T-
cellen van een specifieke subset stijgt wanneer de PASI score afneemt van 'ernstig'naar'matig-
ernstig'. Tijdens behandeling met onercept, waarbij de PASI score afneemt van gemiddeld 34 
(baseline) naar 21 (na 12 weken behandeling), hebben we deze verwachte stijging vanT-cellen 


































































































Tabel I: Veranderingen in expressie van T-cel markers na behandeling met dimethylfumaraat, 
alefacept in combinatie met respectievelijk klasse III corticosteroiden en systemische therapie, en 




De veranderingen m de aantallen T-cellen m het bloed tijdens een antipsoriatische 
behandeling is derhalve de resultante van (ι) de verandering m T-cel aantallen door de 
verbetering van de ziekte-ernst en (u) de verandering m aantallen T-cellen door de behandeling 
zelf Studies waarin een gelijktijdige evaluatie van T-cel subsets m bloed en huid wordt verricht, 
moeten worden uitgevoerd om deze hypothese te ondersteunen 
6.4 Veiligheidsoverwegingen met betrekking tot de verlaging van de 
aantallen T-cellen tijdens deze behandelingen 
Opportunistische infecties zijn beschreven tijdens het gebruik van TNFa-blokkerende middel­
en bij patiënten met rheumatoide arthritis Van immuunsuppressieve medicamenten wordt 
gedacht dat zij maligmteiten kunnen induceren Dit is inderdaad beschreven bij psonasispa-
tienten die behandeld werden met Ciclosporine Daar T-cel gerichte antipsoriatische behan 
delingen m staat zijn het aantal circulerende T-cellen te verminderen (hoofdstukken 3 en 4), 
rijst de vraag of deze behandelingen de zogenaamde 'immuunsurveillance' bij psonasispa-
tienten ook daadwerkelijk zodanig beïnvloeden dat opportunistische infecties en maligmtei-
ten ontstaan 
Infecties en maligmteiten tijdens behandeling met alefacept, anti-TNFa en fumaraten 
Grote aantallen psonasispatienten zijn behandeld met alefacept en de TNFa blokkerende 
therapieën etanercept en infliximab m placebo-gecontroleerde klinische studies De mcidentie 
van ernstige infecties leidend tot klinische opname tijdens het gebruik van alefacept in 
deze studies was 0 9%, maar met significant verschillend van het aantal ernstige infecties 
m de placebo-groep Gecombineerde therapie van alefacept met verschillende topicale 
en systemische behandelingen leidde met tot een verhoogde frequentie van infecties BIJ 
psonasispatienten behandeld met etanercept werden bovenste luchtweginfecties gemeld m 
15,2% Een andere studie rapporteerde infecties in 13% van de met etanercept behandelde 
psonasispatienten tegenover 11% m de placebo -gecontroleerde groep, een met significant 
verschil In de studies worden geen aanwijzingen gevonden voor een verhoogde kans ten 
opzichte van placebo op de ontwikkeling van maligmteiten tijdens het gebruik van alefacept 
of etanercept Beide behandelingen zijn echter slecht een beperkte periode voorgeschreven 
(3-6 maanden) Er kan derhalve niet met zekerheid worden uitgesloten dat een jarenlange 
behandeling mogelijk zou kunnen leiden tot een verhoogde mcidentie van (opportunistische) 
infecties en maligmteiten Om deze reden is een langdurige follow-up periode, waarbij gebruik 
wordt gemaakt van databases van patiënten behandeld met biologicals, noodzakelijk 
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Overfumaraten zijn slechts weinig placebo-gecontroleerde studies beschikbaar. In met 
name Duitstalige landen zijn de laatste decennia echter al vele patiënten behandeld. Er zijn 
geen meldingen bekend van ernstige infecties bij patiënten behandeld met fumaraten, noch 
zijn er aanwijzingen gevonden voor een verhoogde frequentie van maligmteiten. 
In de studies die beschreven worden in hoofdstuk 4, werd geen verhoogd risico van 
alefacept als monotherapie of van alefacept gecombineerd met topicale corticosteroiden en 
klassieke systemische behandelingen op de ontwikkeling van maligmteiten of relevante in-
fecties gevonden Eén patient die tijdens gelijktijdig gebruik van methotrexaat gedurende 3 
weken een luchtweginfectie ontwikkelde vormt hierop een uitzondering. Het TNFa blokke-
rende middel onercept werd goed verdragen door de patiënten behandeld in Nijmegen. Met 
name traden bij hen geen ernstige bijwerkingen en klinisch relevante infecties op BIJ patiën-
ten behandeld m andere centra werden echter wel verschillende ernstige infecties gemeld, 
waaronder sepsis. Om deze reden werd de studie naar onercept wereldwijd gestaakt 
De relatie tussen daling van T-cel subpopulaties en opportunistische infecties en maligmteiten 
Het optreden van opportunistische infecties en maligmteiten bij de patiënten behandeld met 
een biological is met gerelateerd aan de absolute aantallen circulerendeT-cellen CD4, CD8 en 
CD45RO. Het is echter mogelijk dat er bij de patiënten die een infectie ontwikkelden sprake is 
geweest van een eerdere reductie in T-cellen, tijdens behandeling met een biological ofwel 
een ander immuunsuppressief medicament. Tevens zou er sprake geweest kunnen zijn van 
een milde afname m het aantal T-cellen, zonder dat hierbij de ondergrens van normaal werd 
overschreden In de literatuur is weinig informatie aanwezig over reductie van T-cel subsets 
(memory effector cellen, geactiveerde T-cellen en CLA-i- cellen) in relatie tot opportumsctische 
infecties en maligmteiten. 
In onze studies bleven de CD4+ en CD8+ cellen tijdens het gebruik van alefacept, 
onercept en dimethylfumaraat binnen de normaalwaarden. Een patient vertoonde een lichte 
en slechts tijdelijke daling net onder de benedengrens van normaal. Behandeling met alefacept 
monotherapie, alefacept gecombineerd met andere therapieën, en dimethylfumaraat leidde 
tot significante dalingen m verschillende T-cel subsets (tabel I), waaronder memory effector 
cellen, geactiveerde cellen en CLA+ cellen. Afnames van deze celaantallen onder invloed 
van alefacept doen vermoeden dat de patiënten een verhoogd risico lopen op infecties en 
maligmteiten. Soortgelijke afnames werden echter ook tijdens behandeling met fumaraten 
gerapporteerd, een therapie die zich in de loop der tijd danig bewezen heeft Er is niet het 




Concluderend kan worden gesteld dat er geen bewijs voorhanden is dat de reducties 
in absolute aantallen T-cellen zoals geïnduceerd door alefacept en dimethylfumaraat geasso-
cieerd zijn met een verhoogd risico op opportunistische infecties en maligniteiten. Er kan met 
onze studies echter niet uitgesloten worden dat de verstoring van het immuunsysteem geen 
impact op de immuunsurveillance heeft. Patienten die behandeld worden met biologicals 
zouden om deze reden moeten worden opgenomen in databases voor lange-termijn follow 
up van infecties en maligniteiten. 
6.5 Samenvattend 
Patiënten met milde psoriasis hebben vrijwel normale T-cel subsets in het perifere 
bloed 
Patiënten met matig-ernstige psoriasis hebben verhoogde aantallen van de CD4+, 
CD45RO+, CD4+CD25+ en CD4+CLA+ populaties 
Patiënten met ernstige uitingen van psoriasis hebben absolute aantallen T-cellen die 
degene van gezonde proefpersonen en patiënten met milde psoriasis benaderen 
CD45RO+, CD4+CD45RO-I-, CD4-I-CD25+ en CD4+CLA+ cellen laten een consequente 
daling zien na behandeling met alefacept en dimethylfumaraat, wat impliceert dat 
memory effector T-cellen, geactiveerde T-cellen en skin homing T-cellen een belangrijk 
doelwit zijn voor antipsoriatische behandelingen 
Wij veronderstellen dat de stijging in de absolute aantallen van bepaalde T-cel subsets 
tijdens behandeling met onercept, parallel aan de daling van de PASI score van ernstige 
naar matig-ernstige psoriasis, het gevolg is van de T-cel depletie in perifeer bloed 
geassocieerd met de ernstige psoriasis die de patiënten in deze studie hadden 
Tijdens behandeling met de T-cel gerichte therapieën die voor dit proefschrift 
bestudeerd werden, daalden de absolute aantallen van de belangrijke celpopulaties 
CD4+ en CD8+ nooit onder de veilige marge, wat enige geruststelling oplevert met 
betrekking tot de veiligheid van deze middelen 
Verminderingen in aantallen CD45RO+, CD4+CD45RO+, CD4+CD25+ en CD4+CLA+ 
cellen zoals geïnduceerd door alefacept en dimethylfumaraat hebben geen verhoogde 
frequentie van opportunisctische infecties en maligniteiten tot gevolg 
6.6 Suggesties voor de toekomst 
Voor dit proefschrift hebben we ons gefocusseerd op de aantallen psoriasis-relevante 
T-cellen in het perifere bloed. Het functioneren van de T-cellen werd niet onderzocht. 
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Toekomstige studies met aandacht voor de functionaliteit van T-cellen zullen 
aanvullende informatie kunnen geven over de daadwerkelijke relevantie van de 
beschreven T-cellen voor de Pathogenese en behandeling van psoriasis 
De dynamiek van 'T-cel trafficking'tussen het sytemische compartiment en de huid blijft 
onbekend. Migratie studies waarin specifieke T-cellen gelabeld worden en gevolgd 
tijdens hun reis door het lichaam kunnen waardevol, en zijn noodzakelijk om meer 
inzicht te verkrijgen in de rol van de diverse T-cel subsets in psoriasis 
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analysis of variance 
antigen presenting cells 
Cluster of differentiation, term used to define cell-surface molecules that are 
recognized by a given set of monoclonal antibodies. The numbers stands for 
the order of discovery 
subunit of leukocyte function-associated antigen-1 
marker for NK cells 
marker for NK cells, T-cells with memory phenotype 
marker for Β cells 
marker for T-cell activation, subunit of interleukine-2 receptor 
marker for T-cell activation 
pan T-cell marker 
marker for T-helper cells 
marker for naive T-cells 
marker for memory T-cells 
cell adhesion molecule, homing receptor 
marker for cytotoxic T-cells 
marker for NK-cells, T-cells 




Data and Safety Monitoring Board 
fluorescence activated cell sorting 
fumarie acid esters 
provisional name of second-generation fumarate therapy 
fluorescein isothiocyanate 
forward scatter 
human leukocyte antigen 
marker for activation 








































natural killer expressing T-cell receptor 
psoriasis area and severity index 
percentage of patients achieving a PASI reduction of 50% 
percentage of patients achieving a PASI reduction of 75% 
peripheral blood mononuclear cells 
phosphate buffered saline 
phycoerythrin 
physician's global assessment 
propidium iodine 
polymorphonuclear leukocytes 
combination of psoralen and UVA 
combination of retinoid therapy and PUVA 
standard error of the mean 
skin-associated antileukoprotease 
Salford psoriasis index 
side scatter 
T-cell receptor 
Τ helper 1 
Τ helper 2 
tumor necrosis factor 
ultraviolet A 
ultraviolet Β 





Onderzoek, en later het schrijven van een proefschrift, doe je met alleen Hierbij dank ik allen 
die, m meer of minder mate, een bijdrage geleverd aan dit werk in wetenschappelijke en/of 
sociale zin Een aantal mensen wil ik persoonlijk bedanken voor hun betrokkenheid bij mijn 
promotietraject 
Allereerstdankikmijnpromotor,Prof dr dr PCM van de Kerkhof, die mij de mogelijkheid 
heeft geboden dit promotieonderzoek te verrichten Uw engelengeduld en met aflatende 
optimisme zijn zeer belangrijk geweest m de uiteindelijke totstandkoming van dit proefschrift 
Tijdens de werkbesprekingen wist u met uw enthousiasme altijd weer een positieve wending 
te geven aan de in mijn ogen soms tegenvallende resultaten En ondanks dat de combinatie 
van opleiding en promoveren de voortgang met altijd m positieve zin beïnvloed heeft, bleef u 
geduldig en begripvol Bedankt voor het m mij gestelde vertrouwen de afgelopen jaren 
Mijn beide co-promotores, dr EMGJ de Jong en dr PEJ van Erp, wil ik eveneens 
bedanken voor al hun hulp en adviezen de afgelopen 5 jaar Elke, ik heb onze samenwerking 
als bijzonder prettig ervaren Je deur stond altijd open, en hoe druk je zelf ook was, je maakte 
altijd tijd vrij om mijn vragen te beantwoorden of artikelen te lezen Jouw onuitputtelijke 
enthousiasme heeft in belangrijke mate bijgedragen aan mijn werkplezier Piet, de heldere 
introductie die je mij gaf m de wereld van de flowcytometrie is de methodologische basis 
geweest van dit onderzoek Ik kon altijd op je terugvallen als problem solver, als het apparaat 
weer eens met deed wat ik wilde (wat toch met een zekere regelmaat plaatsvond) Ook was 
het je met teveel moeite om af en toe het meten van me over te nemen wanneer de klinische 
werkzaamheden voorrang dienden te krijgen Bedankt voor de fijne samenwerking 
Dr FWMB Preijers van het Centraal Hematologisch Laboratorium wil ik bedanken 
voor zijn nuttige adviezen wat betreft de methodologie van het onderzoek en de interpretatie 
van de resultaten van enkele van mijn experimenten Frank, jouw kritische immunologische 
blik heeft geleid tot waardevolle aanvullingen op, en verhelderende correcties van mijn 
manuscripten, waarvoor mijn dank Bedankt ook voor het verzorgen van de metingen van 
mijn laatste studie 
Marisol, als vaste onderzoeksverpleegkundige ben je de steunpilaar geweest voor 
inmiddels al een flink aantal beginnende en onervaren trialdokters, zo ook voor mij We hebben 
samen heel wat uurtjes doorgebracht op kamer 2, waar je me met raad, maar vooral ook daad, 
hebt bijgestaan bij het zien van alle onderzoekspatienten Buiten werkgerelateerde zaken was 
er bij jou ook altijd tijd voor een babbeltje tussendoor, het liefst met een kopje koffie en wat 
lekkers erbij Bedankt voor de gezellige tijd en je ondersteuning 
Mijn respectievelijke kamergenoten en onderzoekscollegae Wynand,Tim, Jörn, Maartje, 
Manon, Ilse en Marloes wil ik bedanken voor hun gezelligheid, humoren collegialiteit Wynand, 
jouw aanstekelijke lachsalvo's hebben mij menigmaal met je mee doen lachen Bedankt dat 
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je als vraagbaak voorT-cel gerelateerde problemen hebt willen fungeren Tim en Jörn, jullie 
imitaties van wie dan ook en jullie zelf m elkaar gedraaide liedjes, met als kenmerk dat ze 
vooral de hele dag m je hoofd bleven hangen, zal ik mij nog lang heugen1 Bedankt Tim, voor 
je hulp als ik weer eens een met meewerkende computer had Jörn, jou wil ik m het bijzonder 
bedanken voor onze samenwerking bij de trials, voor het verzamelen van de bloedmonsters 
voor mijn onderzoek en voor de T-cel discussies die we gevoerd hebben Manon en Maartje, 
de tijd bij jullie op de kamer was maar kort, maar daarom met minder gezellig1 Bedankt voor 
jullie interesse en fijne gesprekken Ilse, bedankt voor je enorme collegialiteit Je hebt me 
regelmatig werk uit handen genomen zodat ik me weer even op mijn proefschrift kon storten 
Veel succes met je eigen promotie1 Marloes, als huidige kamergenoot heb je de afgelopen 
maanden regelmatig mijn gemopper aan moeten horen over de afronding van dit boekje 
Bedankt voor je luisterende oor, ik beloof betere tijden na 8 december1 
Alle andere arts-assistenten, Marjolein, Lenny, Jeanette, Else, John, Bas, Demia, 
Rosanne, Judith en Denise, wil ik, evenals alle lab- en onderzoeksmedewerkers, stafleden, 
verpleegkundigen, secretaresses en administratief medewerkers bedanken voor hun interesse, 
steun en samenwerking, maar vooral ook voor het creëren van de bijzonder prettige werksfeer 
op de afdeling Dermatologie 
Mijn familie en al mijn vrienden en vriendinnen wil ik bedanken voor de getoonde 
interesse m mijn werkzaamheden, hun medeleven en de nodige ontspannende afleiding die 
zij verzorgd hebben Mijn paranimfen en vriendinnen, Eveline en Krista, bedankt dat jullie mij 
letterlijk en figuurlijk ter zijde willen staan Hoewel gedurende de voltooiing van dit proefschrift 
de frequentie van onze avondjes uit toch enigszins is afgenomen, is de intensiteit van onze 
vriendschap dat gelukkig met1 
Pap en mam, jullie onvoorwaardelijke steun en rotsvast vertrouwen verdienen een 
speciale vermelding m dit dankwoord Bedankt voor alles wat jullie voor me gedaan hebben 
Als allerlaatste, maar zeker met als minste, bedank ik Marco Liefie, wat je voor me 
betekent laat zich met m een paar regels samenvatten Dankjewel voor je support, humor, 
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Behorende bij het proefschrift 
Circulating T-cell subsets in psoriasis 
-relation to disease activity and response to 
systemic treatments-
Annechien Langewouters 
Nijmegen, 8 december 2008 
1. De uitwisseling van T-cellen tussen het cutané en het systemische 
compartiment is de oorzaak van de daling van het aantal psoriasis-
specifieke T-cellen in het bloed bij ernstige psoriasis, (ditproefschrift) 
2. Idealiter zou therapie met biologicals opgestart moeten worden bij 
matig-ernstige psoriasis, (ditproefschrift) 
3. De stijgingen in de CD3+, CD3+CD4+, CD3+CD16.56+ en CD3+C161+ 
celpopulaties tijdens behandeling met onercept zijn het gevolg van de 
parallelle afname van de PASI-score van ernstige naar matig-ernstige 
psoriasis, (dit proefschrift) 
4. Memory effector T-cellen, geactiveerde T-cellen en skin homing T-cellen 
zijn een belangrijk doelwit voor behandelingen gericht tegen psoriasis. 
(dit proefschrift) 
5. Het gebruik van een topicaal corticosteroid gedurende de eerste vier 
weken van de behandeling met alefacept versterkt de systemische 
effecten op T-cellen. (ditproefschrift) 
6. Het gelijktijdig gebruik van een systemische antipsoriatische therapie 
gedurende een behandeling met alefacept verlengt en verbetert het 
effect van alefacept. (dit proefschrift) 
7. De reducties in absolute T-cel aantallen geïnduceerd door alefacept 
en dimethylfumaraat hebben geen verhoogde frequentie van 
opportunistische infecties tot gevolg, (dit proefschrift) 
8. Geneeskunde is de enige wetenschap die voortdurend vecht om de 
redenen voor haar eigen bestaan weg te nemen. 
9. De mens moet wel blijven geloven dat het onbegrijpelijke begrijpelijk 
is, anders ging hij niet verder met onderzoeken. (Goethe) 
10. Karakter is welsprekender dan welbespraaktheid. (Ghandi) 
11. Wie niet vooruit kijkt, blijft achter. 
12. Principes werken het best als ze niet op de proef worden gesteld. 
13. Fouten maken is menselijk, maar om de zaak écht mis te laten gaan 
heb je een computer nodig. 
14. Alleen dromen is slechts dromen, samen dromen is het begin van de 
werkelijkheid. (Braziliaans gezegde) 
15. Wanneer mannen afgeven op de ijdelheid van vrouwen klagen zij over 
gedrag dat zij zelf hebben veroorzaakt. 

